US20230414586A1 - Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds - Google Patents
Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds Download PDFInfo
- Publication number
- US20230414586A1 US20230414586A1 US18/460,648 US202318460648A US2023414586A1 US 20230414586 A1 US20230414586 A1 US 20230414586A1 US 202318460648 A US202318460648 A US 202318460648A US 2023414586 A1 US2023414586 A1 US 2023414586A1
- Authority
- US
- United States
- Prior art keywords
- compound
- exemplary embodiment
- group
- cough
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010011224 Cough Diseases 0.000 title claims abstract description 73
- 208000003251 Pruritus Diseases 0.000 title claims abstract description 73
- 230000007803 itching Effects 0.000 title claims abstract description 50
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 26
- 150000001875 compounds Chemical class 0.000 title claims description 311
- 238000000034 method Methods 0.000 title claims description 57
- 102000004310 Ion Channels Human genes 0.000 title abstract description 14
- 230000002401 inhibitory effect Effects 0.000 title description 5
- 150000003839 salts Chemical class 0.000 claims description 75
- 229910052731 fluorine Inorganic materials 0.000 claims description 44
- 125000001424 substituent group Chemical group 0.000 claims description 17
- 230000001684 chronic effect Effects 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 201000006370 kidney failure Diseases 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 206010008635 Cholestasis Diseases 0.000 claims description 5
- 206010019663 Hepatic failure Diseases 0.000 claims description 5
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 5
- 208000006877 Insect Bites and Stings Diseases 0.000 claims description 5
- 208000024799 Thyroid disease Diseases 0.000 claims description 5
- 208000030961 allergic reaction Diseases 0.000 claims description 5
- 208000007502 anemia Diseases 0.000 claims description 5
- 231100000359 cholestasis Toxicity 0.000 claims description 5
- 230000007870 cholestasis Effects 0.000 claims description 5
- 229960004716 idoxuridine Drugs 0.000 claims description 5
- 208000007903 liver failure Diseases 0.000 claims description 5
- 231100000835 liver failure Toxicity 0.000 claims description 5
- 208000021510 thyroid gland disease Diseases 0.000 claims description 5
- 231100000331 toxic Toxicity 0.000 claims description 5
- 230000002588 toxic effect Effects 0.000 claims description 5
- 206010070488 Upper-airway cough syndrome Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 239000003344 environmental pollutant Substances 0.000 claims description 4
- 231100000719 pollutant Toxicity 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 108090000862 Ion Channels Proteins 0.000 abstract description 13
- 102000003691 T-Type Calcium Channels Human genes 0.000 abstract description 5
- 108090000030 T-Type Calcium Channels Proteins 0.000 abstract description 5
- 206010001497 Agitation Diseases 0.000 abstract description 4
- 230000001537 neural effect Effects 0.000 abstract description 3
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 150000005829 chemical entities Chemical class 0.000 abstract 1
- 108091006146 Channels Proteins 0.000 description 44
- -1 lactam acetamides Chemical class 0.000 description 38
- 239000000203 mixture Substances 0.000 description 35
- 125000005842 heteroatom Chemical group 0.000 description 34
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 33
- 125000004432 carbon atom Chemical group C* 0.000 description 30
- 239000011575 calcium Substances 0.000 description 28
- 238000009472 formulation Methods 0.000 description 28
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 27
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 27
- 208000013116 chronic cough Diseases 0.000 description 21
- 239000008194 pharmaceutical composition Substances 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 18
- 125000003118 aryl group Chemical group 0.000 description 16
- 125000000753 cycloalkyl group Chemical group 0.000 description 15
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 241000124008 Mammalia Species 0.000 description 13
- 125000004404 heteroalkyl group Chemical group 0.000 description 13
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 210000003594 spinal ganglia Anatomy 0.000 description 10
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 229960001985 dextromethorphan Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 125000000623 heterocyclic group Chemical group 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 230000006399 behavior Effects 0.000 description 8
- 125000004474 heteroalkylene group Chemical group 0.000 description 8
- 125000001072 heteroaryl group Chemical group 0.000 description 8
- 125000001183 hydrocarbyl group Chemical group 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 125000000547 substituted alkyl group Chemical group 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 241000700198 Cavia Species 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 229960001340 histamine Drugs 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 239000012453 solvate Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- GSJIGYLGKSBYBC-ALOPSCKCSA-N 3,5-dichloro-N-[[(1S,5R)-3-(3,3-dimethylbutyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]benzamide Chemical compound C1([C@@H]2CN(C[C@@H]21)CCC(C)(C)C)CNC(=O)C1=CC(Cl)=CC(Cl)=C1 GSJIGYLGKSBYBC-ALOPSCKCSA-N 0.000 description 5
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 4
- 208000004454 Hyperalgesia Diseases 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229920001223 polyethylene glycol Chemical group 0.000 description 4
- 238000010149 post-hoc-test Methods 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006748 scratching Methods 0.000 description 4
- 230000002393 scratching effect Effects 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Chemical group 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000000480 calcium channel blocker Substances 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000011737 fluorine Chemical group 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- AGPIHNZOZNKRGT-CYBMUJFWSA-N 5-[(8ar)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazine-2-carbonyl]-4-chloro-2-fluoro-n-(2-fluorophenyl)benzenesulfonamide Chemical compound FC1=CC=CC=C1NS(=O)(=O)C1=CC(C(=O)N2C[C@H]3CCCN3CC2)=C(Cl)C=C1F AGPIHNZOZNKRGT-CYBMUJFWSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 108010073466 Bombesin Receptors Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000047481 Gastrin-releasing peptide receptors Human genes 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 102000002294 Purinergic P2X Receptors Human genes 0.000 description 2
- 108010000836 Purinergic P2X Receptors Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000003566 TRPV1 Human genes 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 208000028311 absence seizure Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 229960001456 adenosine triphosphate Drugs 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 125000004419 alkynylene group Chemical group 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 230000009172 bursting Effects 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 125000005724 cycloalkenylene group Chemical group 0.000 description 2
- 125000002993 cycloalkylene group Chemical group 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 125000003827 glycol group Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000000743 hydrocarbylene group Chemical group 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229960004438 mibefradil Drugs 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- 210000001103 thalamus Anatomy 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 230000001515 vagal effect Effects 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical group CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- GEYDMBNDOVPFJL-CYBMUJFWSA-N 2-(4-cyclopropylphenyl)-n-[(1r)-1-[5-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethyl]acetamide Chemical compound N([C@H](C)C=1N=CC(OCC(F)(F)F)=CC=1)C(=O)CC(C=C1)=CC=C1C1CC1 GEYDMBNDOVPFJL-CYBMUJFWSA-N 0.000 description 1
- UHTQHHLSGVOGQR-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-4-ium-1-yl]ethanesulfonate Chemical compound OCCN1CCN(CCS(O)(=O)=O)CC1.OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 UHTQHHLSGVOGQR-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LGCYVLDNGBSOOW-UHFFFAOYSA-N 2H-benzotriazol-4-ol 1-hydroxybenzotriazole Chemical compound OC1=CC=CC2=C1N=NN2.C1=CC=C2N(O)N=NC2=C1 LGCYVLDNGBSOOW-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- DKNDOKIVCXTFHJ-UHFFFAOYSA-N 3,5-dichloro-n-[[1-[(2,2-dimethyloxan-4-yl)methyl]-4-fluoropiperidin-4-yl]methyl]benzamide Chemical compound C1COC(C)(C)CC1CN1CCC(F)(CNC(=O)C=2C=C(Cl)C=C(Cl)C=2)CC1 DKNDOKIVCXTFHJ-UHFFFAOYSA-N 0.000 description 1
- DKNDOKIVCXTFHJ-HNNXBMFYSA-N 3,5-dichloro-n-[[1-[[(4s)-2,2-dimethyloxan-4-yl]methyl]-4-fluoropiperidin-4-yl]methyl]benzamide Chemical compound C1COC(C)(C)C[C@H]1CN1CCC(F)(CNC(=O)C=2C=C(Cl)C=C(Cl)C=2)CC1 DKNDOKIVCXTFHJ-HNNXBMFYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- RRRCPCOJPQLWEP-UHFFFAOYSA-N 3-hydroxytriazolo[4,5-b]pyridine Chemical compound C1=CN=C2N(O)N=NC2=C1.C1=CN=C2N(O)N=NC2=C1 RRRCPCOJPQLWEP-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- RTDAMORRDXWYPT-UHFFFAOYSA-N 4,5-dichloro-3,6-dioxocyclohexa-1,4-diene-1,2-dicarbonitrile Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O.ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O RTDAMORRDXWYPT-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 102000034573 Channels Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 241000258937 Hemiptera Species 0.000 description 1
- 101000932804 Homo sapiens Voltage-dependent T-type calcium channel subunit alpha-1H Proteins 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010062530 Increased bronchial secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910003849 O-Si Inorganic materials 0.000 description 1
- 229910003872 O—Si Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034759 Petit mal epilepsy Diseases 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 101100288143 Rattus norvegicus Klkb1 gene Proteins 0.000 description 1
- 229910007161 Si(CH3)3 Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QYTDEUPAUMOIOP-UHFFFAOYSA-N TEMPO Chemical group CC1(C)CCCC(C)(C)N1[O] QYTDEUPAUMOIOP-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- UEIZVZWBFCABMS-UHFFFAOYSA-N [benzyl(phenylmethoxy)carbamoyl] hydrogen carbonate Chemical compound C(=O)(O)OC(N(CC1=CC=CC=C1)OCC1=CC=CC=C1)=O UEIZVZWBFCABMS-UHFFFAOYSA-N 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 208000003554 absence epilepsy Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005237 alkyleneamino group Chemical group 0.000 description 1
- 125000005238 alkylenediamino group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 125000005529 alkyleneoxy group Chemical group 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- IUKQLMGVFMDQDP-UHFFFAOYSA-N azane;piperidine Chemical compound N.C1CCNCC1 IUKQLMGVFMDQDP-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 150000001556 benzimidazoles Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000009924 canning Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 210000000188 diaphragm Anatomy 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- JMRYOSQOYJBDOI-UHFFFAOYSA-N dilithium;di(propan-2-yl)azanide Chemical compound [Li+].CC(C)[N-]C(C)C.CC(C)N([Li])C(C)C JMRYOSQOYJBDOI-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical class [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002049 efferent pathway Anatomy 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- OLAMWIPURJGSKE-UHFFFAOYSA-N et2o diethylether Chemical compound CCOCC.CCOCC OLAMWIPURJGSKE-UHFFFAOYSA-N 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 210000000876 intercostal muscle Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- SYJRVVFAAIUVDH-UHFFFAOYSA-N ipa isopropanol Chemical compound CC(C)O.CC(C)O SYJRVVFAAIUVDH-UHFFFAOYSA-N 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- YBSZEWLCECBDIP-UHFFFAOYSA-N n-[bis(dimethylamino)phosphoryl]-n-methylmethanamine Chemical compound CN(C)P(=O)(N(C)C)N(C)C.CN(C)P(=O)(N(C)C)N(C)C YBSZEWLCECBDIP-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- SXESBRNYONQKLV-UHFFFAOYSA-N n-piperidin-1-ylacetamide Chemical class CC(=O)NN1CCCCC1 SXESBRNYONQKLV-UHFFFAOYSA-N 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 210000000584 nodose ganglion Anatomy 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229960005152 pentetrazol Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001451 polypropylene glycol Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000003034 scaffold hopping Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 230000037322 slow-wave sleep Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 210000001679 solitary nucleus Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
- 230000003461 thalamocortical effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
Definitions
- the field of the present invention relates to novel ion channel modulator compounds (inhibitors or antagonists of one type ion channel and/or combination of inhibition of multiple ion channels), compositions including ion channel modulators, and methods of treating conditions and disorders using the compounds and compositions.
- a more particular field involves compounds having selective T-type Ca v3 channel inhibitory effects for mitigating hypersensitive/chronic cough or itching, pharmaceutical formulations including such compounds, and methods for selective treatment of hypersensitive cough or itching.
- Voltage-gated calcium (Ca 2+ channels (VGCC) play an integral role in the regulation of membrane ion conductance, cellular excitability and neurotransmitter release.
- VGCC are composed of the pore-forming al subunit and auxiliary ⁇ 2 ⁇ ppm and ⁇ subunits that modulate channel expression and function.
- the low voltage activated channels is the Ca v3 channel subtype, which mediates T-type calcium currents that may be targeted for treatment of epilepsy, especially children absence epilepsy and chronic pain (Huguenard, 1998, Cribbs et al., 2000, Perez-Reyes et al., 2009, Perez-Reyes, 2010).
- T-type channels are activated at relatively negative membrane potentials ( ⁇ 60 mV).
- Ca 2+ influx through T channels triggers low-threshold Ca 2+ spikes, which in turn elicit a burst of action potentials mediated by voltage-gated sodium (Na + ) channels.
- T channels can be activated by mild depolarization of the cell membrane (Talley et al., 1999, Perez-Reyes, 2003, Perez-Reyes, 2010, Pexton et al., 2011, Todorovic and Jevtovic-Todorovic, 2011).
- the Ca v3.1 and Ca v3.3 channels are expressed predominantly, though not exclusively, in the CNS.
- the Ca v3.2 channel is not only present in the CNS, but also expressed in peripheral nerve cell bodies and nerve endings of afferent fibers (Huguenard, 1998, Cribbs et al., 2000, Perez-Reyes et al., 2009, Perez-Reyes, 2010).
- the Ca v3.2 channel is highly expressed in dorsal root ganglion (DRG) neurons, whereas little Ca v3.1 and virtually no Ca v3.3 are expressed in the small diameter DRG neurons (Nelson et al., 1992).
- the Ca v3.2 channels are also expressed at a lower level in several non-neuronal tissues, including heart, liver, kidney, and pituitary. Both diabetic neuropathy and chronic constriction injury models in rats lead to DRG neuron-specific upregulation of the Ca v3.2 channel and the T current density.
- T-type channel inhibitors have two known uses in the clinic.
- the anti-absence seizure effects of ethosuximide and lamotrigine are thought to be mediated by the inhibition of T channel activity in the thalamus (Gomora et al., 2001, Huguenard, 2002).
- both drugs are weak and not specific against the T channel (Xie et al., 1995, Zhang et al., 1996).
- the antihypertensive effect of mibefradil is conventionally attributed to its inhibition of the T channel.
- mibefradil has poor selectivity with about 3-10 times more potent inhibition of the T-type than of the L-type Ca 2+ current or the voltage-gated Na + current (Avdonin et al., 2000). Because there are no selective T channel blockers, it is unclear whether and to what extend the inhibition of T channel activity at therapeutically relevant concentrations contributes to the therapeutic usefulness of a wide range of drugs.
- T-channel particularly the Ca v3.2 isoform
- a T-channel particularly the Ca v3.2 isoform
- thermal hyperalgesia and mechanical allodynia under pathological conditions such as diabetic neuropathy.
- mechanical allodynia under pathological conditions such as diabetic neuropathy.
- potent and selective T-type Ca 2+ channels have been described in the literature, as exemplified below.
- 1,4-Substituted piperidines for example, “compound 30” (3,5-dichloro-N- ⁇ [1-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyllbenzamide) and “TTA-P2” (3,5-dichloro-N-((1-((2,2-dimethyltetrahydro-2H-pyran-4-yl)methyl)-4-fluoropiperidin-4-yl)methyl)benzamide) were synthesized by Merck and found to potently block the T-Type Ca v3.2 channel [J. Med. Chem. 51, 3692, (2008); J. Med. Chem.
- TTA-A2 suppresses active wake, promotes slow-wave sleep (Kraus et al., 2010), and prevents weight gain in mice on a high-fat diet (Uebele et al., 2009).
- ML218 (3,5-Dichloro-N-[[(1 ⁇ ,5 ⁇ ,6-exo,6 ⁇ )-3-(3,3-dimethylbutyl)-3-azabicyclo [3.1.0]hex-6-yl]methyl]benzamide, CID 45115620) a selective T-Type Ca 2+ inhibitor.
- ML218 possess acceptable in vivo rat PK and was efficacious in a preclinical Parkinson model.
- ML218 is a useful new biologic probe to study T-Type Ca 2+ function in vitro and in vivo (Xie et al., 2010, Xiang et al., 2011).
- lactam acetamides have been described by Abbott and others as Ca v2.2 and Ca v3.2 calcium channel blockers, and ABT-639 has been reported as a Ca v3.2 calcium channel blocker for treatment of diabetic neuropathic pain through peripheral action, because ABT-639 is presumed to not penetrate the blood brain barrier (Jarvis et al., 2014).
- N-Piperidinyl acetamide derivatives as calcium channel blockers have been described by Zalicus Pharmaceuticals, Ltd. (U.S. Pat. No. 8,569,344 (2013); U.S. Pat. No. 8,377,968 (2013)).
- a piperidine-based compound, Z944 inhibits Ca v a channels in a voltage-dependent manner and is able to attenuate thalamic burst firing and suppress absence seizures in rats (Tringham et al., 2012).
- Z944 has shown promising results in clinical Phase I studies of pain in humans (Lee, 2014).
- Cough is a physiological defense mechanism for the clearance of foreign materials and of excessive bronchial secretion in the airways, but it is also a common symptom of a variety of respiratory diseases.
- the cough reflex is triggered by the activation of rapidly adapting receptors (or irritant receptors) within the larynx, trachea and the proximal bronchi, and of C-fiber endings found in the airway walls of bronchi.
- Afferent signals are transmitted through the sensory vagal fibers to the cough center, which has been experimentally identified as being in the region of the solitary nucleus in the medulla within the brain (Kase, Wakita et al. 1970). From the cough center, the impulses travel through the efferent pathways to the respiratory muscles (diaphragm, intercostal and abdominal muscles) and the airways (Irwin, Rosen et al. 1977).
- peripheral neurons may be involved in “hypersensitive cough.” This type of cough is a chronic/persistant cough that can result from an acute cough, or from a cough syndrome or disease such as COPD, asthma, GI reflux, post-nasal drip syndrome and exposure to pollutants including smog and sildfire smoke (see, e.g., Chung and Widdicombe, The Pharmacology and Therapeutics of Cough, In Handbook of Experimental Pharmacology ISSN 0171-2004, Library of Congress Control Number: 200892959, 2009 Springer-Verlag Berlin Heidelberg).
- itch is also a defensive mechanism to protect our body against bugs, harmful chemicals and poisonous plants by causing scratching responses.
- persistant or chronic itchy skin (pruritus) under pathological conditions is a significant unmet clinical problem.
- eczema including atopic dermatitis
- psoriasis a symptom of an underlying internal disease, including liver disease, kidney failure, iron deficiency anemia, thyroid problems or cancers, such as leukemia and lymphoma.
- T-type Ca 2+ channel inhibitors disclosed herein are useful for the treatment and prevention of hypersensitive cough; for example, EX-17, EX-128, EX-130 and EX-132.
- the present inventors have also discovered that T-type Ca 2+ channel inhibitors disclosed herein are useful for the treatment and prevention, for example, EX-31, EX-55, EX-130, EX-132 and AFA-258 (i.e., Z944), AFA-309 and AFA-358.
- the highly potent and selective T-type Ca 2+ channel inhibitors, EX-128 and AFA-258 did not produce anti-itching effects in both of the itch models, chloroquine- and histamine-induced itching.
- the current invention provides compounds, formulations and methods of use for the treatment and prevention of hypersensitive cough and/or itching, in which key ion channels, particularly the T-type Ca 2+ channels are involved.
- the compounds and methods can be used in both human and veterinary medicine.
- the invention provides a method of treating chronic cough, the method comprising the step of administering a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein the compound is:
- R 1 is phenyl substituted with one to three substituents, each of which is a member selected from the group consisting of F, Cl, and CF 3 , thereby treating chronic cough.
- the compound is:
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is:
- the hypersensitive or chronic cough is caused by a disease or syndrome selected from the group consisting of COPD, asthma, GI reflux, post-nasal drip syndrome and chronic exposure to pollutants.
- the compound is administered orally or nasally.
- the method comprising the step of administering a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
- the itching is caused by atopic dermatitis, psoriasis, kidney failure, cholestasis, diabetes, leukemia, lymphoma, eczema, liver failure, anemia, thyroid disease, toxic plant exposure, chemical exposure, smog exposure, insect bites or allergic reaction to a food allergan.
- the compound is administered orally or nasally.
- the invention provides method of treating itching, the method comprising the step of administering a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
- the itching is caused by atopic dermatitis, psoriasis, kidney failure, cholestasis, diabetes, leukemia, lymphoma, eczema, liver failure, anemia, thyroid disease, toxic plant exposure, chemical exposure, smog exposure, insect bites or allergic reaction to a food allergan.
- the compound is administered orally or nasally.
- FIG. 1 B Effects of EX-17 at three doses (3, 10 and 30 mg/kg) and dextromethorphan (60 mg/kg) on the latency to first cough event were determined in citric acid-induced cough in guinea pigs. EX-17 (30 mg/kg) and dextromethorphan (60 mg/kg) caused significant increases the latency compared with the vehicle-treated control group using one-way ANOVA followed by Fisher's LSD post-hoc test (to be double checked).
- FIG. 2 B Effects of three compounds EX-128, EX-130 and EX-132 and dextromethorphan on the latency to first cough event were determined in citric acid-induced cough in guinea pigs. There is a trend of increasing the latency, but not reaching significant difference compared with the vehicle-treated control group using one-way ANOVA followed by Fisher's LSD post-hoc test.
- FIG. 3 A and B Effects of AFA compounds on inhibition of itching scratching behavior in two well-established itching models in mice.
- the present invention provides new methods of treating hypersensitive or chronic cough using inhibitors of selective T-type channel inhibitory compounds.
- Chronic cough a symptom caused by a variety of respiratory disorders affects the quality of life and further exacerbates respiratory pathological conditions.
- Pharmacological interventions are currently confined to treating the cause of cough, and symptomatic treatment options controlling the cough per se with an acceptable therapeutic index are also limited.
- the centrally acting cough therapy such as dextromethorphan and codeine, both of which are opiates used as a cough suppressant in the clinic, depresses the cough center, and is considered the most clinically effective, although sedative and addictive effects can limit their use.
- Local anesthetics that interfere with the conduction of afferent nerve impulses have been shown to be peripherally active antitussive compounds, but their considerable side effects make their use unsuitable.
- Extracellular adenosine 5′-triphosphate (ATP) activates P2X receptors in cell surface and in primary afferent nerves.
- ATP adenosine 5′-triphosphate
- T-type Ca 2+ channels In contrast, little is known about the role of T-type Ca 2+ channels in cough reflex and in persistent cough under pathological conditions.
- T-type Ca 2+ channels mainly the Ca v3.2 subtype expressed in nodose ganglion (Pachuau and Martin-Caraballo, 2007) and play a role in modulation of its axons, vagal nerve excitability
- the conventional T-type Ca 2+ channel locker Ni 2+ 300 ⁇ M
- T-type Ca 2+ channel modulators with regard to antitussive property in a model of citric acid-induced cough in guinea pigs was investigated using new compounds (for example, EX-17, EX-128, EX-130 and EX-132) that potently and selectively inhibit the T-type Ca 2+ channels (see, e.g., PCT/US2016/061918, herein incorporated by reference in its entirety) and compared the results to a clinically used treatment with dextromethorphan.
- new compounds for example, EX-17, EX-128, EX-130 and EX-132
- GRP-GRPR signaling mediates histamine-independent pathway both in acute and chronic itch.
- ion channels mediated the specific itching signaling pathway are currently unknown, though a variety of ion channels such as the voltage-gated sodium (Na) channel, N-type Ca v2.2 , the T-type Ca v3.2 channels and transient receptor potential vanilloid 1 (TRPV1) channels have been suggested to be involved in itch transmission pathways (J Neurol Sci. 1999 Jan. 15; 162(2):162-8. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. Sakurai M1, Kanazawa I.).
- T-type Ca 2+ channel modulators with regard to anti-itching properties in two differenct model of itch in mice was investigated using new compounds (for example, EX-31, EX-55, EX-130, EX-132, AFA-258, AFA-309 and AFA-358) that potently and selectively inhibit the T-type Ca 2+ channels (see, e.g., PCT/US2016/061918, herein incorporated by reference in its entirety)
- the term “method of treating hypersensitive or chronic cough” means partial or full relief from the symptoms of cough or the prevention of hypersensitive cough, often defined as chronic couch of more than eight weeks in duration, including the descriptions of hypersensitive cough provided herein.
- the hypersensitive or chronic cough can be caused by a disease or syndrome selected from the group consisting of COPD, asthma, GI reflux, post-nasal drip syndrome and chronic exposure to pollutants such as smog and wildfire smoke.
- the term “method of treating itching” means partial or full relief from the symptoms of itching or the prevention of itching.
- the itching can be caused by atopic dermatitis, psoriasis, kidney failure, cholestasis, diabetes, leukemia, lymphoma, eczema, liver failure, anemia, thyroid disease, toxic plant exposure, chemical exposure, smog exposure, insect bites or allergic reaction to a food allergan.
- Compound of the invention refers to the compounds discussed herein and salts (e.g. pharmaceutically acceptable salts) of these compounds.
- Alkyl is intended to embrace a univalent saturated linear or branched hydrocarbon chain having the number of carbon atoms specified, or if no number is specified, having 1 to 8 carbon atoms.
- Alkylene refers to a similar group, which is divalent.
- Optionally substituted alkyl refers to either an unsubstituted alkyl group, or an alkyl group substituted with one or more substituents (such as one, two, three, four, or five substituents) selected from the group consisting of —OH, —(C 1 -C 4 alkyl)-OH, halo, fluoro, chloro, bromo, iodo, —(C 1 -C 4 alkyl), —(C 1 -C 4 ) haloalkyl, —(C 1 -C 4 ) perhaloalkyl, —O—(C 1 -C 4 alkyl), —O—(C 1 -C 4 haloalkyl), —O—(C 1 -C 4 perhaloalkyl), —(C 1 -C 4 ) perfluoroalkyl, —(C ⁇ O)—(C 1 -C 4 ) alkyl, —(C ⁇ O)—(
- substituents are —CH 3 , —CH 2 CH 3 , —CF 3 , —CH 2 CF 3 , —CF 2 CF 3 , —OCH 3 , —NH(CH 3 ), —N(CH 3 ) 2 , —SCH 3 , and SO 2 CH 3 .
- Optionally substituted alkylene” groups can be unsubstituted, or substituted in the same manner as substituted alkyl groups.
- Cycloalkyl is intended to embrace a univalent saturated cyclic hydrocarbon chain having the number of carbon atoms specified, or if no number is specified, having 3 to 10 carbon atoms, or 3 to 8 carbon atoms, preferably 3 to 6 carbon atoms. “Cycloalkylene” refers to a similar group, which is divalent. Cycloalkyl and cycloalkylene groups can be unsubstituted, or substituted in the same manner as substituted alkyl groups.
- Alkenyl is intended to embrace a univalent linear or branched hydrocarbon chain having at least one carbon-carbon double bond, and having the number of carbon atoms specified, or if no number is specified, having 2 to 8 carbon atoms.
- Alkenylene refers to a similar group, which is divalent. Alkenyl and alkenylene groups can be unsubstituted, or substituted in the same manner as substituted alkyl groups where chemically possible.
- Cycloalkenyl is intended to embrace a univalent cyclic hydrocarbon chain having at least one carbon-carbon double bond and having the number of carbon atoms specified, or if no number is specified, having 4 to 10 carbon atoms, or 4 to 8 carbon atoms, or 4 to 6 carbon atoms.
- Cycloalkenylene refers to a similar group, which is divalent. Cycloalkenyl and cycloalkenylene groups can be unsubstituted, or substituted in the same manner as substituted alkyl groups where chemically possible.
- Alkynyl is intended to embrace a univalent linear or branched hydrocarbon chain having at least one carbon-carbon triple bond, and having the number of carbon atoms specified, or if no number is specified, having 2 to 8 carbon atoms.
- Alkynylene refers to a similar group, which is divalent. Alkynyl and alkynylene groups can be unsubstituted, or substituted in the same manner as substituted alkyl groups where chemically possible.
- Aryl is defined as a univalent aromatic ring system.
- Aryl groups include monocyclic aromatic rings and polycyclic aromatic ring systems containing the number of carbon atoms specified, or if no number is specified, containing six to twenty carbon atoms. In other embodiments, aryl groups may contain six to ten carbon atoms.
- Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quino
- aryl groups can be unsubstituted. In other embodiments, aryl groups can be substituted with, for example, one, two, three or more substituents independently selected from the group consisting of —OH, —(C1-C4 alkyl)-OH, halo, fluoro, chloro, bromo, iodo, —(C 1 -C 4 alkyl), —(C 1 -C 4 ) haloalkyl, —(C 1 -C 4 ) perhaloalkyl, —O—(C 1 -C 4 alkyl), —O—(C 1 -C 4 haloalkyl), —O—(C 1 -C 4 perhaloalkyl), —(C 1 -C 4 ) perfluoroalkyl, —(C ⁇ O)—(C 1 -C 4 ) alkyl, —(C ⁇ O)—(C 1 -C 4 ) haloalkyl,
- any of the aryl and heteroaryl groups is optionally substituted, e.g., with one or more groups referred to herein as an “aryl group substituent”.
- aryl group substituent refers to a similar group, which is divalent.
- heteroaryl refers to aryl groups (or rings) that contain from one to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized.
- a heteroaryl group can be attached to the remainder of the molecule through a heteroatom.
- Hydrocarbyl is defined as a univalent hydrocarbon group, that is, a group comprised of hydrogen and carbon, whether aliphatic or aromatic, acyclic or cyclic, or any combination of, or all of, aliphatic, aromatic, acyclic and cyclic. Hydrocarbyl groups have the number of carbon atoms specified, or if no number is specified, having 1 to 10 carbon atoms. “Hydrocarbylene” refers to a similar group, which is divalent. Hydrocarbyl and hydrocarbylene groups can be unsubstituted, or substituted in the same manner as substituted alkyl groups where chemically possible.
- Heterocycle or a “heterocyclic group” is defined as a ring system which contains the number of carbon atoms specified, and one or more heteroatoms (such as one to six heteroatoms, or one to three heteroatoms, or one heteroatom), where heteroatoms include, but are not limited to, oxygen, nitrogen, sulfur, and phosphorus.
- Heteroaryl is defined as an aromatic ring system which contains the number of carbon atoms specified, and one or more heteroatoms (such as one to six heteroatoms, or one to three heteroatoms, or one heteroatom), where heteroatoms include, but are not limited to, oxygen, nitrogen, sulfur, and phosphorus; heteroaryl groups are a subset of heterocyclic groups.
- heteroatoms for heterocyclyl and heteroaryl groups are selected from the group consisting of oxygen and nitrogen.
- heterocyclic groups may contain two to twenty carbon atoms and one to six heteroatoms, two to twelve carbon atoms and one to four heteroatoms, two to twelve carbon atoms and one to three heteroatoms, two to ten carbon atoms and one to three heteroatoms, two to six carbon atoms and one to three heteroatoms, or two to six carbon atoms and two to four heteroatoms.
- heterocyclic groups can be unsubstituted.
- heterocyclic groups can be substituted on any chemically possible valence with for example, one, two, or three substituents independently selected from the group consisting of —OH, —(C 1 -C 4 alkyl)-OH, halo, fluoro, chloro, bromo, iodo, —(C 1 -C 4 alkyl), —(C 1 -C 4 ) haloalkyl, —(C 1 -C 4 ) perhaloalkyl, —O—(C 1 -C 4 alkyl), —O—(C 1 -C 4 haloalkyl), —O—(C 1 -C 4 perhaloalkyl), —(C 1 -C 4 ) perfluoroalkyl, —(C ⁇ O)—(C 1 -C 4 ) alkyl, —(C ⁇ O)—(C 1 -C 4 ) haloalkyl, —(C ⁇ O)——(C 1
- heterocycles include aziridine, oxirane, oxetane, azetidine, pyrrolidine, pyrrole, tetrahydrofuran, furan, thiolane, thiophene, imidazolidine, imidazole, pyrazolidine, pyrazole, 1,2,3-triazole, 1,2,4-triazole, piperidine, pyridine, pyran, piperazine, and morpholine.
- heteroalkyl group is defined as a univalent hydrocarbyl group, where one or more of the carbon atoms have been independently replaced by a heteroatom at any chemically possible location, where heteroatoms include, but are not limited to, oxygen, nitrogen, sulfur, and phosphorus. Heteroalkyl groups have the number of carbon atoms specified, or if no number is specified, having 1 to 10 carbon atoms, and also at least one heteroatom, such as 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 heteroatoms, 1 to 2 heteroatoms, or one heteroatom. “Heteroalkylene” refers to a similar group, which is divalent.
- Heteroalkyl and heteroalkylene groups can be unsubstituted, or substituted in the same manner as substituted alkyl groups where chemically possible.
- heteroalkyl and heteroalkylene groups include, but are not limited to, ethylene glycol and polyethylene glycol moieties, such as (—CH 2 CH 2 —O) n —H (a monovalent heterohalkyl group) and (—CH 2 CH 2 —O—) n (a divalent heteroalkylene group) where n is an integer from 1 to 12 inclusive, and propylene glycol and polypropylene glycol moieties, such as (—CH 2 CH(CH 3 )—O—) n —H (a monovalent heteroalkyl group) and (—CH 2 CH(CH 3 )—O—) n — (a divalent heteroalkylene group) where n is an integer from 1 to 12 inclusive.
- the heteroatom(s) O, N and S and Si may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule.
- Examples include, but are not limited to, —CH 2 —CH 2 —O—CH 3 , —CH 2 —CH 2 —NH—CH 3 , —CH 2 —CH 2 —N(CH 3 )—CH 3 , —CH 2 —S—CH 2 —CH 3 , —CH 2 —CH 2 , —S(O)—CH 3 , —CH 2 —CH 2 —S(O) 2 —CH 3 , —CH ⁇ CH—O—CH 3 , —Si(CH 3 ) 3 , —CH 2 —CH ⁇ N—OCH 3 , and —CH ⁇ C—N(CH 3 )—CH 3 .
- heteroalkylene by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified, but not limited by, —CH 2 —CH 2 —S—CH 2 —CH 2 —and —CH 2 —S—CH 2 —CH 2 —NH—CH 2 —.
- heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula —CO 2 R′— represents both —C(O)OR′ and —OC(O)R′.
- groups described above can be attached to the remainder of the molecule at any chemically possible location on the fragment, including attachment via a substituent when the group is substituted.
- groups are typically attached by replacement of a hydrogen, hydroxyl, methyl, or methoxy group on a “complete” molecule to generate the appropriate fragment, and a bond is drawn from the open valence on the fragment to the remainder of the molecule.
- attachment of the heteroalkyl group —CH 2 —O—CH 3 proceeds by removal of a hydrogen from one of the methyl groups of CH 3 —O—CH 3 , to generate the heteroalkyl fragment —CH 2 —O—CH 3 , from which a bond is drawn from the open valence to the remainder of the molecule.
- references to “about” a value or parameter herein includes (and describes) variations that are directed to that value or parameter per se. For example, description referring to “about X” includes description of “X”.
- subject By “subject,” “individual,” or “patient” is meant an individual organism, preferably a vertebrate, more preferably a mammal, most preferably a human.
- the salts of the compounds comprise pharmaceutically acceptable salts.
- Pharmaceutically acceptable salts are those salts which can be administered as drugs or pharmaceuticals to humans and/or animals and which, upon administration, retain at least some of the biological activity of the free compound (neutral compound or non-salt compound).
- the desired salt of a basic compound may be prepared by methods known to those of skill in the art by treating the compound with an acid. Examples of inorganic acids include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid.
- organic acids include, but are not limited to, formic acid, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, sulfonic acids, and salicylic acid.
- Salts of basic compounds with amino acids, such as aspartate salts and glutamate salts can also be prepared.
- the desired salt of an acidic compound can be prepared by methods known to those of skill in the art by treating the compound with a base.
- Examples of inorganic salts of acid compounds include, but are not limited to, alkali metal and alkaline earth salts, such as sodium salts, potassium salts, magnesium salts, and calcium salts; ammonium salts; and aluminum salts.
- Examples of organic salts of acid compounds include, but are not limited to, procaine, dibenzylamine, N-ethylpiperidine, N,N′-dibenzylethylenediamine, and triethylamine salts. Salts of acidic compounds with amino acids, such as lysine salts, can also be prepared.
- salts of acidic compounds with amino acids such as lysine salts, can also be prepared.
- terapéuticaally effective amount means that amount of a compound, material, or formulation comprising a compound of the present invention which is effective for producing some desired therapeutic effect by inhibition of a T-Channel in at least a sub-population of cells in an animal, thereby blocking or lessening the biological consequences of that pathway in the treated cells, at a reasonable benefit/risk ratio applicable to any medical treatment.
- the invention provides a method for treating a condition described herein in a mammal, the method comprises administering to the mammal a therapeutically effective amount of a compound described herein, or a compound according to a formula described herein, or a pharmaceutically acceptable salt thereof, sufficient to treat the condition, thereby treating the condition.
- the mammal is in need of treatment with the compound.
- the mammal is a dog, a cat, a horse, a pig, a cow, a sheep, a mouse, a guinea pig, or a rat.
- the mammal is a human.
- the invention provides a method for treating a condition described herein in a mammal, the method comprises administering to the mammal a therapeutically effective amount of a pharmaceutical formulation described herein, sufficient to treat the condition, thereby treating the condition.
- the mammal is in need of treatment with the pharmaceutical formulation.
- the mammal is not otherwise in need of treatment with the pharmaceutical formulation.
- the mammal is a mouse or a rat.
- the mammal is a human.
- IC 50 refers to the concentration causing a 50% inhibition of the specific binding of the control substance.
- the invention provides a compound of the invention.
- the invention provides a compound described herein, or a salt thereof.
- the salt of a compound described herein is a pharmaceutically acceptable salt.
- the invention provides a compound described herein, or a pharmaceutically acceptable salt thereof.
- the invention provides a compound described in a formula provided herein.
- the invention provides a compound described herein.
- One object of the present invention is to provide a compound, or a pharmaceutically acceptable salt thereof, which can be used to treat chronic cough or itching, of the general structure:
- R 1 is selected from substituted or unsubstituted benzyl or a substituted or unsubstituted polycyclic cycloalkyl ring, e.g., adamantyl.
- R 1 is substituted adamantyl.
- R 1 is substituted adamant-1-yl.
- R 1 is unsubstituted adamantyl.
- R 1 is unsubstituted adamant-l-yl.
- R 1 is substituted by 1, 2, 3 or 4 non-hydrogen substituents selected from halo, haloalkyl, substituted or unsubstituted alkoxy, and cyano.
- the compounds of the invention used to treat chronic cough or itching have a structure according to Formula I, wherein R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , and X are as described herein, R 1 is of the formula:
- A, B, C and D are independently selected from “aryl group substituents”; and the indices a, b, c, and d are independently selected from 0 and 1.
- the compounds of the invention used to treat chronic cough or itching have a structure according to Formula I, wherein R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , and X are as described herein, A, B, C and D are independently selected from CN, Cl, Br, F, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted C 1 -C 6 haloalkyl, and substituted or unsubstituted C 1 -C 6 alkoxy.
- R 2 is selected from C 1 -C 10 straight chain or branched substituted or unsubstituted C 1 -C 6 alkyl, and C 1 -C 10 substituted or unsubstituted C 1 -C 6 alkyl heteroalkyl.
- R 2 includes substituted alkyl or substituted heteroalkyl groups, which are substituted with amide, oxo, substituted or unsubstituted aryl or substituted or unsubstituted heterocycloalkyl.
- exemplary substituted aryl groups include substituted or unsubstituted phenyl, and an exemplary heterocycloalkyl moiety is an oxygen-containing heterocycle.
- a compound of the invention used to treat chronic cough or itching has the formula:
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11a , R 11b , and X are as described herein, wherein q is an integer selected from 1, 2, 3, 4 and 5.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and X are as described herein, wherein R 11 and R 11b are members each independently selected from H, methyl, and fluorine.
- R 11a is H and R 11b is F.
- RI, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and X are as described herein, q is 1, R 11a is F and R 11b is F.
- a compound of the invention used to treat chronic cough or itching has the formula:
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and X are as described herein, q is an integer selected from 1, 2, 3, 4 and 5.
- a compound of the invention used to treat chronic cough or itching has the formula:
- a compound of the invention used to treat chronic cough or itching has the formula:
- a compound of the invention used to treat chronic cough or itching has the formula:
- a compound of the invention used to treat chronic cough or itching has the formula:
- a compound of the invention used to treat chronic cough or itching has the formula:
- R 1 is substituted or unsubstituted benzyl or substituted or unsubstituted adamantyl.
- q, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and X are as described herein, wherein Ri is substituted phenyl.
- R 1 is unsubstituted phenyl.
- q, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and X are as described herein, wherein Ri is substituted or unsubstituted adamantyl.
- q, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and X are as described herein, wherein R 1 is
- R 1a and R 1b are members each independently selected from halo, haloalkyl, substituted or unsubstituted alkoxy, and cyano.
- R 1 is
- R 1a and R 1b are members each independently selected from F, Cl, Br, CF 3 , methoxy, methyl, and CN.
- R 1 is
- R 1a and R 1b are members each independently selected from F, Cl, and CF 3 .
- the compound used to treat chronic cough or itching has the following formula:
- the compound is according to a formula described herein, and R 1 is phenyl substituted with one to three substituents, each of which is a member selected from the group consisting of F, Cl, and CF 3 .
- the compound is according to a formula described herein, and R 1 is phenyl substituted with one substituent which is a member selected from the group consisting of F, Cl, and CF 3 .
- the compound is according to a formula described herein, and R 2 is phenyl substituted with two substituents which are members each individually selected from the group consisting of F, Cl, and CF 3 .
- the compound is according to a formula described herein, and R 2 is phenyl substituted with thee substituents which are members each individually selected from the group consisting of F, Cl, and CF 3 .
- the compound has the following formula:
- the compound used to treat chronic cough or itching is
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- R 1 and R 2 are as described herein.
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- R 1 is unsubstituted adamantyl.
- the compound is
- R 1 is unsubstituted adamant-1-yl.
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- R 2 , R 1a and R 1b are as described herein.
- the compound is according to a formula described herein which contains R 1a and R 1b , wherein R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is according to a formula described herein which contains R 1 a and R 1b , wherein R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is according to a formula described herein which contains R 1a and R 1b , wherein R 1a is as described herein, and R 1b is F.
- the compound is according to a formula described herein which contains R 1a and R 1b , wherein R 1a is as described herein, and R 1b is Cl. In an exemplary embodiment, the compound is according to a formula described herein which contains R 1a and R 1b , wherein R 1a is as described herein, and R 1b is CF 3 . In an exemplary embodiment, the compound is according to a formula described herein which contains R 1a and R 1b , wherein R 1b is as described herein, and R 1a is F. In an exemplary embodiment, the compound is according to a formula described herein which contains R 1a and R 1b , wherein R 1b is as described herein, and R 1a is Cl. In an exemplary embodiment, the compound is according to a formula described herein which contains R 1a and R 1b , wherein R 1b is as described herein, and R 1a is CF 3 . In an exemplary embodiment, the compound is according to a formula described herein which contains R 1a and R
- R 2 , R 1a and R 1b are as described herein.
- the compound is
- R 2 , R 1a and R 1b are as described herein.
- the compound is
- R 2 , R 1a and R 1b are as described herein.
- the compound is
- R 2 , R 1a and R 1b are as described herein.
- the compound is
- R 2 , R 1a and R 1b are as described herein.
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- R 2 , R 1a and R 1b are as described herein.
- the compound is according to a formula described herein which contains R 1a and R 1b , wherein R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is according to a formula described herein which contains R 1 a and R 1b , wherein R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is according to a formula described herein which contains R 1a and R 1b , wherein R 1a is as described herein, and R 1b is F.
- the compound is according to a formula described herein which contains R 1a and R 1b , wherein R 1a is as described herein, and R 1b is Cl. In an exemplary embodiment, the compound is according to a formula described herein which contains R 1a and R 1b , wherein R 1a is as described herein, and R 1b is CF 3 . In an exemplary embodiment, the compound is according to a formula described herein which contains R 1a and R 1b , wherein R 1b is as described herein, and R 1a is F. In an exemplary embodiment, the compound is according to a formula described herein which contains R 1 a and R 1b , wherein R 1b is as described herein, and Ria is Cl. In an exemplary embodiment, the compound is according to a formula described herein which contains R 1a and R 1b , wherein R 1b is as described herein, and R 1a is CF 3 . In an exemplary embodiment, the compound is
- R 2 , R 1a and R 1b are as described herein.
- the compound is
- R 2 , R 1a and R 1b are as described herein.
- the compound is
- R 2 , R 1a and R 1b are as described herein.
- the compound is
- R 2 , R 1a and R 1b are as described herein.
- the compound is
- R 2 , R 1a and R 1b are as described herein.
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- R 2 is as described herein, and R 1 is unsubstituted adamantyl.
- the compound is
- R 2 is as described herein, and R 1 is unsubstituted adamant-1-yl.
- the compound is
- R 2 is as described herein, and R 1 is unsubstituted adamantyl.
- the compound is
- R 2 is as described herein, and R 1 is unsubstituted adamant-1-yl.
- the compound is
- R 2 is as described herein, and R 1 is unsubstituted adamantyl.
- the compound is
- R 2 is as described herein, and R 1 is unsubstituted adamant-1-yl.
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- R 1 is as described herein.
- the compound is
- R 1 is as described herein.
- the compound is
- R 1 is as described herein.
- the compound is
- R 1 is as described herein.
- the compound is
- R 1 is as described herein.
- the compound is
- R 1 is as described herein.
- the compound is
- R 1 is as described herein.
- the compound is
- R 1 is as described herein.
- the compound is
- R 1 is as described herein.
- the compound is
- R 1 is as described herein.
- the compound is
- R 1 is as described herein.
- the compound is
- R 1 is as described herein.
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- X is as described herein, and R 1 is unsubstituted adamant-1-yl.
- the compound is
- X is as described herein, and R 1 is unsubstituted adamant-1-yl.
- the compound is
- X is as described herein, and R 1 is unsubstituted adamant-1-yl.
- the compound is
- X is as described herein, and R 1 is unsubstituted adamant-1-yl.
- the compound is
- X is as described herein, and R 1 is unsubstituted adamant-1-yl.
- the compound is
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is
- R 1a and R 1b are members each independently selected from the group consisting of F, Cl, and CF 3 .
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- R 1 is unsubstituted adamantyl.
- the compound is
- R 1 is unsubstituted adamant-1-yl.
- the compound is
- R 1 is unsubstituted adamantyl.
- the compound is
- R 1 is unsubstituted adamant-1-yl.
- the compound is
- R 1 is unsubstituted adamantyl.
- the compound is
- R 1 is unsubstituted adamant-1-yl.
- the compound is
- R 1 is unsubstituted adamantyl.
- the compound is
- R 1 is unsubstituted adamant-1-yl.
- the compound is
- R 1 is unsubstituted adamantyl.
- the compound is
- R 1 is unsubstituted adamant-1-yl.
- the compound is
- R 1 is unsubstituted adamantyl.
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- R 1 is unsubstituted adamant-1-yl.
- the compound is
- R 1 is unsubstituted adamantyl.
- the compound is
- R 1 is unsubstituted adamant-1-yl.
- the compound is
- R 1 is unsubstituted adamantyl.
- the compound is
- R 1 is unsubstituted adamant-1-yl.
- the compound is
- R 1 is unsubstituted adamantyl.
- the compound is
- R 1 is unsubstituted adamant-1-yl.
- the compound is
- R 1 is unsubstituted adamantyl.
- the compound is
- R 1 is unsubstituted adamant-1-yl.
- the compound is
- R 1 is unsubstituted adamantyl.
- the compound is
- R 1 is unsubstituted adamant-1-yl.
- the compound is
- R 1 is unsubstituted adamantyl.
- the compound is
- R 1 is unsubstituted adamant-1-yl.
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- the compound is
- the compound is
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- the compound is
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- the compound is
- the compound is
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- the compound is
- the compound is
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- the compound is
- the compound is
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- the compound is
- the compound is
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- the compound is
- the compound is
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- the compound is
- the compound is
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- the compound is any pharmaceutically acceptable salt thereof, wherein R 1 is unsubstituted adamant-1-yl.
- the compound is
- the compound is any pharmaceutically acceptable salt thereof, wherein R 1 is unsubstituted adamant-1-yl.
- the compound is
- R 1 is unsubstituted adamant-1-yl.
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- the compound is
- the compound is
- the structure of AFA-358 is
- the structure of AFA-309 is
- the structure of AFA-258 is
- the structure of AFA-353 is
- AFA-309, 353 and 358 are novel T-type Ca v a channel modulators used in the treatment of pathological conditions, including pain, hypersensitive cough and itching.
- the invention also provides a pharmaceutical formulation comprising a therapeutically effective amount of a compound according to Formula I or individually disclosed herein.
- the formulation further includes a pharmaceutically acceptable carrier.
- the invention also provides a method for treating hypersensitive cough or ticking responsive to selective inhibition of the T Channel known as the Ca v3.2 channel comprising administering to a mammal a therapeutically effective amount of a compound according to Formula I or individually disclosed herein.
- the present invention provides compounds which are selective T-Channel inhibitory compounds useful for relief of hypersensitive cough or itching.
- the invention also includes, where chemically possible, all stereoisomers and geometric isomers of the compounds, including diastereomers, enantiomers, and cis/trans (E/Z) isomers.
- the invention also includes mixtures of stereoisomers and/or geometric isomers in any ratio, including, but not limited to, racemic mixtures. Unless stereochemistry is explicitly indicated in a structure, the structure is intended to embrace all possible stereoisomers of the compound depicted. If stereochemistry is explicitly indicated for one portion or portions of a molecule, but not for another portion or portions of a molecule, the structure is intended to embrace all possible stereoisomers for the portion or portions where stereochemistry is not explicitly indicated.
- the compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
- the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 3 H) , iodine-125 ( 125 I) or carbon-14 ( 14 C) All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.
- the invention includes all isotopologues of the compounds disclosed herein, such as, for example, deuterated derivatives of the compounds (where H can be 2 H, i.e., D).
- compounds that are considered to possess activity as T-Channel inhibitors are those displaying 50% inhibition of the Ca ++ voltage (IC 50 ) at a concentration of not higher than about 100 ⁇ M, preferably, not higher than about 10 ⁇ M, more preferably not higher than about 1 ⁇ M and most preferably not higher than about 100 nM.
- a protecting group refers to a group which is used to mask a functionality during a process step in which it would otherwise react, but in which reaction is undesirable.
- the protecting group prevents reaction at that step, but may be subsequently removed to expose the original functionality.
- the removal or “deprotection” occurs after the completion of the reaction or reactions in which the functionality would interfere.
- the compounds of the present invention may be prepared by the methods illustrated in the general reaction schemes as, for example, described below, or by modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants that are in themselves known, but are not mentioned here.
- the starting materials for example in the case of suitably substituted benzimidazole ring compounds, are either commercially available, synthesized as described in the examples or may be obtained by the methods well known to persons of skill in the art.
- the present invention further provides pharmaceutical formulations comprising as active agents, the compounds described herein.
- the invention is a pharmaceutical formulation comprising a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the invention is a pharmaceutical formulation comprising a therapeutically effective amount of a compound of a formula described herein, or a pharmaceutically acceptable salt thereof.
- the invention is a pharmaceutical formulation comprising a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- the invention is a pharmaceutical formulation comprising a therapeutically effective amount of a compound of a formula described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- the invention is a pharmaceutical formulation described herein, wherein the formulation is in a unit dosage form.
- a “pharmaceutical formulation” refers to a preparation of one or more of the compounds described herein, or physiologically acceptable salts or solvates (including hydrates) thereof, with other chemical components such as physiologically suitable carriers and excipients.
- a prophylactic or therapeutic dose typically varies with the nature and severity of the condition to be treated and the route of administration.
- the dose, and perhaps the dose frequency, will also vary according to the age, body weight and response of the individual patient. In general, a dose ranges from about mg to about 7000 mg, preferably about 1 mg to about 100 mg, and more preferably, about 25 mg to about 50 mg, in single or divided doses.
- a dose may range from about mg to about 500 mg, and preferably, about 100 mg to about 500 mg. Such doses may be administered 1, 2, 3, 4, 5, 6 or more times in a day. It may be recommended that children, patients over 65 years old, and those with impaired renal or hepatic function, initially receive low doses and that the dosage is titrated based on individual responses and/or blood levels. It may be necessary to use dosages outside these ranges in some cases, as will be apparent to those in the art. Further, it is noted that the clinician or treating physician knows how and when to interrupt, adjust or terminate therapy in conjunction with individual patient's response.
- compositions for use in accordance with the present invention thus may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active compounds into preparations which, can be used pharmaceutically.
- the carriers must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Proper formulation is dependent upon the route of administration chosen.
- Compounds that inhibit T-Channels can be formulated as pharmaceutical formulations and administered to a mammalian subject, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., oral, rectal, topical (including dermal, buccal, sublingual, and intraocular), or parenteral, by intravenous, intramuscular, topical, transdermal, intradermal, intraarticular, or subcutaneous routes.
- a mammalian subject such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., oral, rectal, topical (including dermal, buccal, sublingual, and intraocular), or parenteral, by intravenous, intramuscular, topical, transdermal, intradermal, intraarticular, or subcutaneous routes.
- the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art.
- Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient.
- Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores.
- Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carbomethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP).
- disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar or alginic acid or a salt thereof such as sodium alginate.
- an enteric coating may be useful as it is may be desirable to prevent exposure of the compounds of the invention to the gastric environment.
- compositions which can be used orally, include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- the push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers may be added.
- Formulations for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia. All formulations for oral administration should be in dosages suitable for the chosen route of administration.
- the compounds of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's or Ringer's solution or physiological saline buffer.
- physiologically compatible buffers such as Hank's or Ringer's solution or physiological saline buffer.
- penetrants appropriate to the barrier to be permeated may be used in the formulation.
- penetrants including for example DMSO or polyethylene glycol, are known in the art.
- the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide.
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
- compositions for parenteral administration include aqueous and non-aqueous sterile injection solutions, which may contain anti-oxidants, buffers, bacteriostats and solutes, which render the formulation isotonic with the blood of the intended recipient.
- Formulations also include aqueous and non-aqueous sterile suspensions, which may include suspending agents and thickening agents.
- Pharmaceutical formulations for parenteral administration in an aqueous solution contain the active ingredients in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions.
- Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes.
- Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran.
- the suspension may also contain suitable stabilizers or agents, which increase the solubility of the compounds, to allow for the preparation of highly concentrated solutions.
- the formulations may be presented in unit-dose of multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of a sterile liquid carrier, for example saline, phosphate-buffered saline (PBS) or the like, immediately prior to use.
- a sterile liquid carrier for example saline, phosphate-buffered saline (PBS) or the like.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- the compounds of the present invention may also be formulated in rectal formulations such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.
- dosing can also be a single administration of a slow release formulations, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.
- the amount of a formulation to be administered will, of course, be dependent on many factors including the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician.
- the compounds of the invention may be administered orally or via injection at a dose from 0.001 to 250 mg/kg per day.
- the dose range for adult humans is generally from 0.5 mg to 10 g/day.
- Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of compound of the invention which is effective at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually around 10 mg to 200 mg.
- the precise amount of compound administered to a patient will be the responsibility of the attendant physician. However, the dose employed will depend on a number of factors, including the age and sex of the patient, the precise disorder being treated, and its severity. Also, the route of administration may vary depending on the condition and its severity.
- solvate refers to a compound described herein and/or from Formula I in the solid state, wherein molecules of a suitable solvent are incorporated in the crystal lattice.
- a suitable solvent for therapeutic administration is physiologically tolerable at the dosage administered. Examples of suitable solvents for therapeutic administration are ethanol and water. When water is the solvent, the solvate is referred to as a hydrate. In general, solvates are formed by dissolving the compound in the appropriate solvent and isolating the solvate by cooling or using an antisolvent.
- the solvate is typically dried or azeotroped under ambient conditions.
- Inclusion complexes are described in Remington: The Science and Practice of Pharmacy 19th Ed. (1995) volume 1, page 176—177, which is incorporated herein by reference. The most commonly employed inclusion complexes are those with cyclodextrins, and all cyclodextrin complexes, natural and synthetic, are specifically encompassed within the claims.
- pharmaceutically acceptable salt refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids and bases and organic acids and bases.
- salts may be prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids.
- Suitable pharmaceutically acceptable acid addition salts for the compounds of the present invention include acetic, benzenesulfonic (besylate), benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric acid, p-toluenesulfonic, and the like.
- suitable pharmaceutically acceptable base addition salts for the compounds of the present invention include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.
- preventing refers to administering a medicament beforehand to forestall or obtund an attack.
- the person of ordinary skill in the medical art recognizes that the term “prevent” is not an absolute term. In the medical art it is understood to refer to the prophylactic administration of a drug to substantially diminish the likelihood or seriousness of a condition, and this is the sense intended herein.
- formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
- the formulations may be presented in a packaging device or dispenser, which may contain one or more unit dosage forms containing the active ingredient.
- a packaging device include metal or plastic foil, such as a blister pack and a nebulizer for inhalation.
- the packaging device or dispenser may be accompanied by instructions for administration.
- Formulations comprising a compound of the present invention formulated in a compatible pharmaceutical carrier may also be placed in an appropriate container and labeled for treatment of an indicated condition.
- embodiments recited as “consisting essentially of” or “consisting of” with respect to their various elements can also be recited as “comprising” as applied to those elements.
- embodiments recited as “consisting essentially of” with respect to their various elements can also be recited as “consisting of” as applied to those elements, and embodiments recited as “consisting of” with respect to their various elements can also be recited as “consisting essentially of” as applied to those elements.
- the compound or formulation contains the components expressly listed, and may contain other components which do not substantially affect the condition being treated. That is, the compound or formulation either does not contain any other components which do substantially affect the condition being treated other than those components expressly listed; or, if the compound or formulation does contain extra components other than those listed which substantially affect the condition being treated, the compound or formulation does not contain a sufficient concentration or amount of those extra components to substantially affect the condition being treated.
- the method contains the steps listed, and may contain other steps that do not substantially affect the condition being treated, but the method does not contain any other steps which substantially affect the condition being treated other than those steps expressly listed.
- Guinea pigs male, 280 g body weight, Hartley Crl:HA, Charles River
- Cough was induced with citric acid aerosol inhalation and cough assessment by human manual score (Gallico, Borghi et al. 1994).
- Individual animals were placed in a 4L plexiglas observation chambers continuously filled with 17.5% citric acid aerosol.
- EX-17 produced a dose-dependent inhibition of the number of cough events with reduction of 7.2, 23.3 and 36.8% at dose of 3, 10 and 30 mg/kg, respectively ( FIG. 1 A ).
- EX-17 produced comparable inhibition as dextromethorphan (40.0% at 60 mg/kg, p.o.).
- EX-17 also caused increases in the latencies of the first cough in a dose-dependent manner. Only at 30 mg/kg EX-17 and dextromethorphan hydrobromide (60 mg/kg, p.o.) reached significance under the experimental conditions ( FIG. 1 B ).
- EX-compounds EX-128, -130 and -132 were tested by orally administering30 minutes while dextromethorphan hydrobromide (60 mg/kg, p.o.) 60 minutes prior to the citric acid inhalation, based on their PK profiles.
- dextromethorphan hydrobromide 60 mg/kg, p.o. 60 minutes prior to the citric acid inhalation, based on their PK profiles.
- compounds EX-128 and dextromethorphan significantly reduced the number of cough events with reduction of 39.1% and 42.6%, respectively ( FIG. 2 A ).
- EX-130 and -132 showed a trend towards reducing the number of cough events with reduction of 33% and 15.7, respectively, without reaching significance.
- the latencies to the first cough were increased with three compounds and the benchmark, but none of them reached significance level under the experimental conditions ( FIG. 2 B ).
- a representative panel of AFA/EX compounds was investigated on a variety of recombinant human ion channels expressed in mammalian cells and on native ion channels in dissociated rat dorsal root ganglion (DRG) neurons. As shown in Table 1, the selected 10 AFA-compounds produced differential modulations on different ion currents mediated by the selected ion channels. Thus, this panel of compounds was next investigated on their effects on itching scratching behavior in two well-established itching models in mice.
- DRG dissociated rat dorsal root ganglion
- mice were shaved at the nape of the neck 2-3 days before experiments.
- mice were individually placed in small plastic chambers (12 cm L ⁇ 9.5 W ⁇ 12 H) that inserted into an ordinary homecage at least 30 min for habituation and recorded baseline of behavior using a video camera and a piezoelectric floor sensor operated by a validated homecage behavioral monitory system, SmartCage, which can monitor multiple mouse scratching behaviors simultaneously.
- mice were administered an intraperitoneally (i.p.) injected 30 min prior to itching induction.
- Mice were given an intradermal injection of 50 ⁇ l of a pruritogen, chloroquine or histamine into the nape of the neck.
- mice were returned to their chambers and were continually recorded by the piezoelectric floor sensor for 30 min.
- Human manual scoring of itching scratch behavior in real-time and confirmed by video and/or piezoelectric recordings offline. The itch behavior was quantified by counting the number of scratches in a blinded to the treatment manner.
- a scratch was counted when a mouse lifted its hindpaw to scratch the shaved region and returned the paw to the floor or to the mouth for licking.
- the piezoelectric signals with a larger and regular waveform distinguished from normal homecage activity were analyzed off-line to objectively quantifying scratch episodes and durations.
Abstract
The present invention is directed towards new chemical entities which primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity, particularly involved in hypersensitive cough or itching.
Description
- This application claims priority to U.S. patent application Ser. No. 16/115,549, filed Aug. 28, 2018, which is incorporated by reference in its entirety. U.S. patent application Ser. No. 16/115,549 is related to PCT/US2016/061918, herein incorporated by reference in its entirety.
- This invention was made with Government support under Grant 1 R44 N5086343-01 awarded by the National Institute of Neurological Disorders and Stroke, National Institute of Health. The Government has certain rights in this invention.
- The field of the present invention relates to novel ion channel modulator compounds (inhibitors or antagonists of one type ion channel and/or combination of inhibition of multiple ion channels), compositions including ion channel modulators, and methods of treating conditions and disorders using the compounds and compositions. A more particular field involves compounds having selective T-type Cav3 channel inhibitory effects for mitigating hypersensitive/chronic cough or itching, pharmaceutical formulations including such compounds, and methods for selective treatment of hypersensitive cough or itching.
- Voltage-gated calcium (Ca2+ channels (VGCC) play an integral role in the regulation of membrane ion conductance, cellular excitability and neurotransmitter release. VGCC are composed of the pore-forming al subunit and auxiliary α2δ ppm and β subunits that modulate channel expression and function. Among the low voltage activated channels is the Cav3 channel subtype, which mediates T-type calcium currents that may be targeted for treatment of epilepsy, especially children absence epilepsy and chronic pain (Huguenard, 1998, Cribbs et al., 2000, Perez-Reyes et al., 2009, Perez-Reyes, 2010).
- The T-type or “low voltage-activated” calcium channels are so named because they open for shorter duration (T=transient) than the L-type (L=long lasting) calcium channels. T-type channels are activated at relatively negative membrane potentials (˜−60 mV). In many types of neurons, Ca2+ influx through T channels triggers low-threshold Ca2+ spikes, which in turn elicit a burst of action potentials mediated by voltage-gated sodium (Na+) channels. Brief burst firing is thought to play an important role in the synchronized activity of the thalamus and neuronal pacemaker under physiological conditions, but it also underlies a wide range of thalamocortical dysrhythmias under pathological conditions such as neuropathic pain or seizures. T channels can be activated by mild depolarization of the cell membrane (Talley et al., 1999, Perez-Reyes, 2003, Perez-Reyes, 2010, Pexton et al., 2011, Todorovic and Jevtovic-Todorovic, 2011).
- Molecular cloning has revealed three distinct T channel proteins, designated Cav3.1, Cav3.2 and Cav3.3. The Cav3.1 and Cav3.3 channels are expressed predominantly, though not exclusively, in the CNS. In contrast, the Cav3.2 channel is not only present in the CNS, but also expressed in peripheral nerve cell bodies and nerve endings of afferent fibers (Huguenard, 1998, Cribbs et al., 2000, Perez-Reyes et al., 2009, Perez-Reyes, 2010). The Cav3.2 channel is highly expressed in dorsal root ganglion (DRG) neurons, whereas little Cav3.1 and virtually no Cav3.3 are expressed in the small diameter DRG neurons (Nelson et al., 1992). The Cav3.2 channels are also expressed at a lower level in several non-neuronal tissues, including heart, liver, kidney, and pituitary. Both diabetic neuropathy and chronic constriction injury models in rats lead to DRG neuron-specific upregulation of the Cav3.2 channel and the T current density. This pathological adaptation results in enhanced excitability of sensory neurons and causes hyperalgesia and allodynia (Jagodic et al., 2007, Jagodic et al., 2008, Latham et al., 2009, Messinger et al., 2009, Yue et al., 2013). Conversely, knockout or antisense knockdown of the Cav3.2 isoform produces analgesic effects (Messinger et al., 2009).
- T-type channel inhibitors have two known uses in the clinic. The anti-absence seizure effects of ethosuximide and lamotrigine are thought to be mediated by the inhibition of T channel activity in the thalamus (Gomora et al., 2001, Huguenard, 2002). However, both drugs are weak and not specific against the T channel (Xie et al., 1995, Zhang et al., 1996). The antihypertensive effect of mibefradil is conventionally attributed to its inhibition of the T channel. However, mibefradil has poor selectivity with about 3-10 times more potent inhibition of the T-type than of the L-type Ca2+ current or the voltage-gated Na+ current (Avdonin et al., 2000). Because there are no selective T channel blockers, it is unclear whether and to what extend the inhibition of T channel activity at therapeutically relevant concentrations contributes to the therapeutic usefulness of a wide range of drugs.
- Targeting a T-channel, particularly the Cav3.2 isoform, would be highly useful, for example, in reduction of thermal hyperalgesia and mechanical allodynia under pathological conditions such as diabetic neuropathy. Several efforts to discover potent and selective T-type Ca2+ channels have been described in the literature, as exemplified below.
- 1,4-Substituted piperidines, for example, “
compound 30” (3,5-dichloro-N-Δ[1-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyllbenzamide) and “TTA-P2” (3,5-dichloro-N-((1-((2,2-dimethyltetrahydro-2H-pyran-4-yl)methyl)-4-fluoropiperidin-4-yl)methyl)benzamide) were synthesized by Merck and found to potently block the T-Type Cav3.2 channel [J. Med. Chem. 51, 3692, (2008); J. Med. Chem. 51, 6471, (2008); US 2010/0222387; US 2013/8501773]. TTA-A2 suppresses active wake, promotes slow-wave sleep (Kraus et al., 2010), and prevents weight gain in mice on a high-fat diet (Uebele et al., 2009). - A scaffold hopping approach afforded ML218 (3,5-Dichloro-N-[[(1α,5α,6-exo,6α)-3-(3,3-dimethylbutyl)-3-azabicyclo [3.1.0]hex-6-yl]methyl]benzamide, CID 45115620) a selective T-Type Ca2+ inhibitor. ML218 possess acceptable in vivo rat PK and was efficacious in a preclinical Parkinson model. Thus, ML218 is a useful new biologic probe to study T-Type Ca2+ function in vitro and in vivo (Xie et al., 2010, Xiang et al., 2011).
- Certain lactam acetamides have been described by Abbott and others as Cav2.2 and Cav3.2 calcium channel blockers, and ABT-639 has been reported as a Cav3.2 calcium channel blocker for treatment of diabetic neuropathic pain through peripheral action, because ABT-639 is presumed to not penetrate the blood brain barrier (Jarvis et al., 2014).
- N-Piperidinyl acetamide derivatives as calcium channel blockers have been described by Zalicus Pharmaceuticals, Ltd. (U.S. Pat. No. 8,569,344 (2013); U.S. Pat. No. 8,377,968 (2013)). A piperidine-based compound, Z944, inhibits Ca v a channels in a voltage-dependent manner and is able to attenuate thalamic burst firing and suppress absence seizures in rats (Tringham et al., 2012). Z944 has shown promising results in clinical Phase I studies of pain in humans (Lee, 2014).
- Despite the fact that many T-type Ca2+ channel inhibitors have been discovered and have advanced to different stages of development, no FDA-approved selective T-type channel inhibitory compounds are available for clinical applications.
- Cough is a physiological defense mechanism for the clearance of foreign materials and of excessive bronchial secretion in the airways, but it is also a common symptom of a variety of respiratory diseases. The cough reflex is triggered by the activation of rapidly adapting receptors (or irritant receptors) within the larynx, trachea and the proximal bronchi, and of C-fiber endings found in the airway walls of bronchi. Afferent signals are transmitted through the sensory vagal fibers to the cough center, which has been experimentally identified as being in the region of the solitary nucleus in the medulla within the brain (Kase, Wakita et al. 1970). From the cough center, the impulses travel through the efferent pathways to the respiratory muscles (diaphragm, intercostal and abdominal muscles) and the airways (Irwin, Rosen et al. 1977).
- Experimental studies have shown that peripheral neurons may be involved in “hypersensitive cough.” This type of cough is a chronic/persistant cough that can result from an acute cough, or from a cough syndrome or disease such as COPD, asthma, GI reflux, post-nasal drip syndrome and exposure to pollutants including smog and sildfire smoke (see, e.g., Chung and Widdicombe, The Pharmacology and Therapeutics of Cough, In Handbook of Experimental Pharmacology ISSN 0171-2004, Library of Congress Control Number: 200892959, 2009 Springer-Verlag Berlin Heidelberg).
- Similar to cough, which is a defensive mechanism to eliminate irratants or pathogens within the airway under physiological conditions, itch is also a defensive mechanism to protect our body against bugs, harmful chemicals and poisonous plants by causing scratching responses. However, persistant or chronic itchy skin (pruritus) under pathological conditions is a significant unmet clinical problem. Over 30 million people in U.S. suffer from eczema, including atopic dermatitis, and about 7 million people suffer from psoriasis. Furthermore, pruritus can be a symptom of an underlying internal disease, including liver disease, kidney failure, iron deficiency anemia, thyroid problems or cancers, such as leukemia and lymphoma. In hemodialysis patients, the prevalence of chronic kidney disease associated pruritus is high as 55% in both men and women (Prevalence of chronic kidney disease-associated pruritus among adult dialysis patients: A meta-analysis of cross-sectional studies, Hu et al.).
- Currently, there is no efficient therapy for the irresistible itch symptoms of various chronic diseases associated pruritus or itching. A recent study implicated Cav 3.2 channel activation in NaHS-induced itching in experimental animals (Wang et al., Scientific Reports 5:16768 (2015), suggesting the Cav 3.2 channel might be a target for anti-iching compounds.
- In fact, the present inventors have discovered that T-type Ca2+ channel inhibitors disclosed herein are useful for the treatment and prevention of hypersensitive cough; for example, EX-17, EX-128, EX-130 and EX-132. The present inventors have also discovered that T-type Ca2+ channel inhibitors disclosed herein are useful for the treatment and prevention, for example, EX-31, EX-55, EX-130, EX-132 and AFA-258 (i.e., Z944), AFA-309 and AFA-358. The highly potent and selective T-type Ca2+ channel inhibitors, EX-128 and AFA-258 did not produce anti-itching effects in both of the itch models, chloroquine- and histamine-induced itching. Unexpectedly, however, compounds that are mixed modulators of key ion channels, including voltage-gated Na channels, exemplified by EX-31, EX-130 and AFA-358, are effective against both chloroquine- and histamine-induced models of itching.
- The current invention provides compounds, formulations and methods of use for the treatment and prevention of hypersensitive cough and/or itching, in which key ion channels, particularly the T-type Ca2+ channels are involved. The compounds and methods can be used in both human and veterinary medicine.
- In one aspect, the invention provides a method of treating chronic cough, the method comprising the step of administering a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein the compound is:
- wherein R1 is phenyl substituted with one to three substituents, each of which is a member selected from the group consisting of F, Cl, and CF3, thereby treating chronic cough.
- In one embodiment, the compound is:
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3.
- In another embodiment, the compound is:
- In another embodiment, the hypersensitive or chronic cough is caused by a disease or syndrome selected from the group consisting of COPD, asthma, GI reflux, post-nasal drip syndrome and chronic exposure to pollutants.
- In another embodiment the compound is administered orally or nasally.
- In one aspect, the method comprising the step of administering a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
- In one embodiment, the itching is caused by atopic dermatitis, psoriasis, kidney failure, cholestasis, diabetes, leukemia, lymphoma, eczema, liver failure, anemia, thyroid disease, toxic plant exposure, chemical exposure, smog exposure, insect bites or allergic reaction to a food allergan.
- In another embodiment, the compound is administered orally or nasally.
- In another aspect, the invention provides method of treating itching, the method comprising the step of administering a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
- In one embodimemt, the itching is caused by atopic dermatitis, psoriasis, kidney failure, cholestasis, diabetes, leukemia, lymphoma, eczema, liver failure, anemia, thyroid disease, toxic plant exposure, chemical exposure, smog exposure, insect bites or allergic reaction to a food allergan.
- In another embodiment, the compound is administered orally or nasally.
-
FIG. 1A .FIG. 1A . Effects of a representative compound EX-17 at three doses (3, 10 and 30 mg/kg) and the benchmark dextromethorphan (60 mg/kg) on the number of cough events were determined in a model of citric acid-induced cough in naive, conscious guinea pigs. All test compounds were formulated with hydroxyl Propyl Cellulose and given orally by gavage (p.o.). Data are given as mean±SEM of n=8 animals per group. P-value (<0.05 indicated by *) represent significant difference compared with the vehicle-treated control group using one-way ANOVA followed by Fisher's LSD post-hoc test. -
FIG. 1B . Effects of EX-17 at three doses (3, 10 and 30 mg/kg) and dextromethorphan (60 mg/kg) on the latency to first cough event were determined in citric acid-induced cough in guinea pigs. EX-17 (30 mg/kg) and dextromethorphan (60 mg/kg) caused significant increases the latency compared with the vehicle-treated control group using one-way ANOVA followed by Fisher's LSD post-hoc test (to be double checked). -
FIG. 2A . Effects of three compounds EX-128, EX-130 and EX-132 (each 30 mg/kg) and the benchmark dextromethorphan (60 mg/kg/kg) on the number of cough events were determined in a model of citric acid-induced cough in naive, conscious guinea pigs. All test compounds were formulated with 0.5% hydroxyl Propyl Cellulose and given via p.o. Data are given as mean±SEM of n=8 animals per group. P-value (<0.05 indicated by *) represent significant difference compared with the vehicle-treated control group using one-way ANOVA followed by Fisher's LSD post-hoc test. -
FIG. 2B . Effects of three compounds EX-128, EX-130 and EX-132 and dextromethorphan on the latency to first cough event were determined in citric acid-induced cough in guinea pigs. There is a trend of increasing the latency, but not reaching significant difference compared with the vehicle-treated control group using one-way ANOVA followed by Fisher's LSD post-hoc test. -
FIG. 3A and B: Effects of AFA compounds on inhibition of itching scratching behavior in two well-established itching models in mice. - As described herein, the present invention provides new methods of treating hypersensitive or chronic cough using inhibitors of selective T-type channel inhibitory compounds.
- Chronic cough a symptom caused by a variety of respiratory disorders affects the quality of life and further exacerbates respiratory pathological conditions. Pharmacological interventions are currently confined to treating the cause of cough, and symptomatic treatment options controlling the cough per se with an acceptable therapeutic index are also limited. The centrally acting cough therapy, such as dextromethorphan and codeine, both of which are opiates used as a cough suppressant in the clinic, depresses the cough center, and is considered the most clinically effective, although sedative and addictive effects can limit their use. Local anesthetics that interfere with the conduction of afferent nerve impulses have been shown to be peripherally active antitussive compounds, but their considerable side effects make their use unsuitable.
Extracellular adenosine 5′-triphosphate (ATP) activates P2X receptors in cell surface and in primary afferent nerves. The development of selective blockers of different P2X receptors has led to clinical trials of their effectiveness in the management of cough, pain, inflammation and certain neurodegenerative diseases (North 2016). - In contrast, little is known about the role of T-type Ca2+ channels in cough reflex and in persistent cough under pathological conditions. Although T-type Ca2+ channels, mainly the Cav3.2 subtype expressed in nodose ganglion (Pachuau and Martin-Caraballo, 2007) and play a role in modulation of its axons, vagal nerve excitability, the conventional T-type Ca2+ channel locker Ni2+ (300 μM) apparently did not alter the responses of guinea pig tracheobronchial cough receptor fibers or nociceptors to citric acid (Canning and Chou, 2004). Therefore, the possible efficacy of T-type Ca2+ channel modulators with regard to antitussive property in a model of citric acid-induced cough in guinea pigs was investigated using new compounds (for example, EX-17, EX-128, EX-130 and EX-132) that potently and selectively inhibit the T-type Ca2+ channels (see, e.g., PCT/US2016/061918, herein incorporated by reference in its entirety) and compared the results to a clinically used treatment with dextromethorphan.
- Many chronic itch disorders are not responsive to commonly used anti-histamine drugs suggesting that histamine-independent itch models may be more relevant for identification of novel target and discovery of new compounds for chronic itch treatment. A recent identification of the first spinal cord itch receptor, gastrin-releasing peptide receptor (GRPR) triggered extensive molecular studies of itch transmission pathways in the nervous system. GRP-GRPR signaling mediates histamine-independent pathway both in acute and chronic itch. Which ion channels mediated the specific itching signaling pathway are currently unknown, though a variety of ion channels such as the voltage-gated sodium (Na) channel, N-type Cav2.2, the T-type Cav3.2 channels and transient receptor potential vanilloid 1 (TRPV1) channels have been suggested to be involved in itch transmission pathways (J Neurol Sci. 1999 Jan. 15; 162(2):162-8. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. Sakurai M1, Kanazawa I.). Therefore, the possible efficacy of T-type Ca2+ channel modulators with regard to anti-itching properties in two differenct model of itch in mice was investigated using new compounds (for example, EX-31, EX-55, EX-130, EX-132, AFA-258, AFA-309 and AFA-358) that potently and selectively inhibit the T-type Ca2+ channels (see, e.g., PCT/US2016/061918, herein incorporated by reference in its entirety)
- Below are definitions of representative types of hypersensitive cough and itching in which the compounds, pharmaceutical formulations and methods find use in treating.
- The term “method of treating hypersensitive or chronic cough” means partial or full relief from the symptoms of cough or the prevention of hypersensitive cough, often defined as chronic couch of more than eight weeks in duration, including the descriptions of hypersensitive cough provided herein. The hypersensitive or chronic cough can be caused by a disease or syndrome selected from the group consisting of COPD, asthma, GI reflux, post-nasal drip syndrome and chronic exposure to pollutants such as smog and wildfire smoke.
- The term “method of treating itching” means partial or full relief from the symptoms of itching or the prevention of itching. The itching can be caused by atopic dermatitis, psoriasis, kidney failure, cholestasis, diabetes, leukemia, lymphoma, eczema, liver failure, anemia, thyroid disease, toxic plant exposure, chemical exposure, smog exposure, insect bites or allergic reaction to a food allergan.
- “Compound of the invention,” as used herein, refers to the compounds discussed herein and salts (e.g. pharmaceutically acceptable salts) of these compounds.
- “Alkyl” is intended to embrace a univalent saturated linear or branched hydrocarbon chain having the number of carbon atoms specified, or if no number is specified, having 1 to 8 carbon atoms. “Alkylene” refers to a similar group, which is divalent. “Optionally substituted” alkyl refers to either an unsubstituted alkyl group, or an alkyl group substituted with one or more substituents (such as one, two, three, four, or five substituents) selected from the group consisting of —OH, —(C1-C4 alkyl)-OH, halo, fluoro, chloro, bromo, iodo, —(C1-C4 alkyl), —(C1-C4) haloalkyl, —(C1-C4) perhaloalkyl, —O—(C1-C4 alkyl), —O—(C1-C4 haloalkyl), —O—(C1-C4 perhaloalkyl), —(C1-C4) perfluoroalkyl, —(C═O)—(C1-C4) alkyl, —(C═O)—(C1-C4) haloalkyl, —(C═O)—(C1-C4) perhaloalkyl, —NH2, —NH (C1-C4 alkyl), —N(C1-C4 alkyl) (C1-C4 alkyl) (where each C1-C4 alkyl is chosen independently of the other), —NO 2 , —CN, isocyano (NC—), oxo (═O), —C(═O) H, —C(═O)—(C1-C4 alkyl), —COOH, —C(═O)—O—(C1-C4 alkyl), —C(═O)NH 2 , —C(=)ONH(C1-C4 alkyl), —C(═O)N(C1-C4 alkyl) (C1-C4 alkyl) (where each C1-C4 alkyl is chosen independently of the other), —SH, —(C1-C4 alkyl)-SH, —S-(C1-C4 alkyl), —S (═O)—(C1-C4 alkyl), —S0 2-(C1-C4 alkyl), and -SO2- (C1-C4 perfluoroalkyl). Examples of such substituents are —CH3, —CH2 CH3, —CF3, —CH2 CF3, —CF2 CF3, —OCH3, —NH(CH3), —N(CH3)2, —SCH3, and SO2 CH3. “Optionally substituted alkylene” groups can be unsubstituted, or substituted in the same manner as substituted alkyl groups.
- “Cycloalkyl” is intended to embrace a univalent saturated cyclic hydrocarbon chain having the number of carbon atoms specified, or if no number is specified, having 3 to 10 carbon atoms, or 3 to 8 carbon atoms, preferably 3 to 6 carbon atoms. “Cycloalkylene” refers to a similar group, which is divalent. Cycloalkyl and cycloalkylene groups can be unsubstituted, or substituted in the same manner as substituted alkyl groups.
- “Alkenyl” is intended to embrace a univalent linear or branched hydrocarbon chain having at least one carbon-carbon double bond, and having the number of carbon atoms specified, or if no number is specified, having 2 to 8 carbon atoms. “Alkenylene” refers to a similar group, which is divalent. Alkenyl and alkenylene groups can be unsubstituted, or substituted in the same manner as substituted alkyl groups where chemically possible.
- “Cycloalkenyl” is intended to embrace a univalent cyclic hydrocarbon chain having at least one carbon-carbon double bond and having the number of carbon atoms specified, or if no number is specified, having 4 to 10 carbon atoms, or 4 to 8 carbon atoms, or 4 to 6 carbon atoms. “Cycloalkenylene” refers to a similar group, which is divalent. Cycloalkenyl and cycloalkenylene groups can be unsubstituted, or substituted in the same manner as substituted alkyl groups where chemically possible.
- “Alkynyl” is intended to embrace a univalent linear or branched hydrocarbon chain having at least one carbon-carbon triple bond, and having the number of carbon atoms specified, or if no number is specified, having 2 to 8 carbon atoms. “Alkynylene” refers to a similar group, which is divalent. Alkynyl and alkynylene groups can be unsubstituted, or substituted in the same manner as substituted alkyl groups where chemically possible.
- “Aryl” is defined as a univalent aromatic ring system. Aryl groups include monocyclic aromatic rings and polycyclic aromatic ring systems containing the number of carbon atoms specified, or if no number is specified, containing six to twenty carbon atoms. In other embodiments, aryl groups may contain six to ten carbon atoms. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl.
- In some embodiments, aryl groups can be unsubstituted. In other embodiments, aryl groups can be substituted with, for example, one, two, three or more substituents independently selected from the group consisting of —OH, —(C1-C4 alkyl)-OH, halo, fluoro, chloro, bromo, iodo, —(C1-C4 alkyl), —(C1-C4) haloalkyl, —(C1-C4) perhaloalkyl, —O—(C1-C4 alkyl), —O—(C1-C4 haloalkyl), —O—(C1-C4 perhaloalkyl), —(C1-C4) perfluoroalkyl, —(C═O)—(C1-C4) alkyl, —(C═O)—(C1-C4) haloalkyl, —(C═O)—(C1-C4) perhaloalkyl, —NH2, —NH (C1-C4 alkyl), —N(C1-C4 alkyl) (C1-C4 alkyl) (where each C1-C4 alkyl is chosen independently of the other), —NO2, —CN, (NC—), —C(═O) H, —C(═O)—(C1-C4 alkyl), —COOH, —C(═O)—O—(C1-C4 alkyl), —C(═O)NH 2, —C(=)ONH(C1-C4 alkyl), —C(═O)N(C1-C4 alkyl) (C1-C4 alkyl) (where each C1-C4 alkyl is chosen independently of the other), —SH, —(C1-C4 alkyl)-SH and —S—C1-C4 alkyl. In some embodiments, any of the aryl and heteroaryl groups is optionally substituted, e.g., with one or more groups referred to herein as an “aryl group substituent”. “Arylene” refers to a similar group, which is divalent.
- The term “heteroaryl” refers to aryl groups (or rings) that contain from one to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom.
- “Hydrocarbyl” is defined as a univalent hydrocarbon group, that is, a group comprised of hydrogen and carbon, whether aliphatic or aromatic, acyclic or cyclic, or any combination of, or all of, aliphatic, aromatic, acyclic and cyclic. Hydrocarbyl groups have the number of carbon atoms specified, or if no number is specified, having 1 to 10 carbon atoms. “Hydrocarbylene” refers to a similar group, which is divalent. Hydrocarbyl and hydrocarbylene groups can be unsubstituted, or substituted in the same manner as substituted alkyl groups where chemically possible.
- “Heterocycle” or a “heterocyclic group” is defined as a ring system which contains the number of carbon atoms specified, and one or more heteroatoms (such as one to six heteroatoms, or one to three heteroatoms, or one heteroatom), where heteroatoms include, but are not limited to, oxygen, nitrogen, sulfur, and phosphorus. “Heteroaryl” is defined as an aromatic ring system which contains the number of carbon atoms specified, and one or more heteroatoms (such as one to six heteroatoms, or one to three heteroatoms, or one heteroatom), where heteroatoms include, but are not limited to, oxygen, nitrogen, sulfur, and phosphorus; heteroaryl groups are a subset of heterocyclic groups. In some embodiments, heteroatoms for heterocyclyl and heteroaryl groups are selected from the group consisting of oxygen and nitrogen. In various embodiments, heterocyclic groups may contain two to twenty carbon atoms and one to six heteroatoms, two to twelve carbon atoms and one to four heteroatoms, two to twelve carbon atoms and one to three heteroatoms, two to ten carbon atoms and one to three heteroatoms, two to six carbon atoms and one to three heteroatoms, or two to six carbon atoms and two to four heteroatoms. In some embodiments, heterocyclic groups can be unsubstituted. In other embodiments, heterocyclic groups can be substituted on any chemically possible valence with for example, one, two, or three substituents independently selected from the group consisting of —OH, —(C1-C4 alkyl)-OH, halo, fluoro, chloro, bromo, iodo, —(C1-C4 alkyl), —(C1-C4) haloalkyl, —(C1-C4) perhaloalkyl, —O—(C1-C4 alkyl), —O—(C1-C4 haloalkyl), —O—(C1-C4 perhaloalkyl), —(C1-C4) perfluoroalkyl, —(C═O)—(C1-C4) alkyl, —(C═O)—(C1-C4) haloalkyl, —(C═O)—(C1-C4) perhaloalkyl, —NH2, —NH (C1-C4 alkyl), —N (C1-C4 alkyl) (C1-C4 alkyl) (where each C1-C4 alkyl is chosen independently of the other), —NO2, —CN, (NC—), —C(═O) H, —C(═O)—(C1-C4 alkyl), —COOH, —C(═O)—O—(C1-C4 alkyl), —C(═O)NH2, —C(=)ONH(C1-C4 alkyl), —C(═O)N(C1-C4 alkyl) (C1-C4 alkyl) (where each C1-C4 alkyl is chosen independently of the other), —SH, —(C1-C4 alkyl)-SH and —S-C1-C4 alkyl. Examples of heterocycles include aziridine, oxirane, oxetane, azetidine, pyrrolidine, pyrrole, tetrahydrofuran, furan, thiolane, thiophene, imidazolidine, imidazole, pyrazolidine, pyrazole, 1,2,3-triazole, 1,2,4-triazole, piperidine, pyridine, pyran, piperazine, and morpholine.
- A “heteroalkyl” group is defined as a univalent hydrocarbyl group, where one or more of the carbon atoms have been independently replaced by a heteroatom at any chemically possible location, where heteroatoms include, but are not limited to, oxygen, nitrogen, sulfur, and phosphorus. Heteroalkyl groups have the number of carbon atoms specified, or if no number is specified, having 1 to 10 carbon atoms, and also at least one heteroatom, such as 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 heteroatoms, 1 to 2 heteroatoms, or one heteroatom. “Heteroalkylene” refers to a similar group, which is divalent. Heteroalkyl and heteroalkylene groups can be unsubstituted, or substituted in the same manner as substituted alkyl groups where chemically possible. Examples of heteroalkyl and heteroalkylene groups include, but are not limited to, ethylene glycol and polyethylene glycol moieties, such as (—CH2CH2—O)n—H (a monovalent heterohalkyl group) and (—CH2CH2—O—)n (a divalent heteroalkylene group) where n is an integer from 1 to 12 inclusive, and propylene glycol and polypropylene glycol moieties, such as (—CH2 CH(CH3)—O—)n—H (a monovalent heteroalkyl group) and (—CH2CH(CH3)—O—)n— (a divalent heteroalkylene group) where n is an integer from 1 to 12 inclusive. The heteroatom(s) O, N and S and Si may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Examples include, but are not limited to, —CH2—CH2—O—CH3, —CH2—CH2—NH—CH3, —CH2—CH2—N(CH3)—CH3, —CH2—S—CH2—CH3, —CH2—CH2, —S(O)—CH3, —CH2—CH2—S(O)2—CH3, —CH═CH—O—CH3, —Si(CH3)3, —CH2—CH═N—OCH3, and —CH═C—N(CH3)—CH3. Up to two heteroatoms may be consecutive, such as, for example, —CH2—NH—OCH3 and —CH2—O—Si(CH3) 3. Similarly, the term “heteroalkylene” by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified, but not limited by, —CH2—CH2—S—CH2—CH2—and —CH2—S—CH2—CH2—NH—CH2—. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula —CO2R′— represents both —C(O)OR′ and —OC(O)R′.
- The various groups described above can be attached to the remainder of the molecule at any chemically possible location on the fragment, including attachment via a substituent when the group is substituted. For the purposes of drawing the structures, groups are typically attached by replacement of a hydrogen, hydroxyl, methyl, or methoxy group on a “complete” molecule to generate the appropriate fragment, and a bond is drawn from the open valence on the fragment to the remainder of the molecule. For example, attachment of the heteroalkyl group —CH2—O—CH3 proceeds by removal of a hydrogen from one of the methyl groups of CH3—O—CH3, to generate the heteroalkyl fragment —CH2—O—CH3, from which a bond is drawn from the open valence to the remainder of the molecule.
- Reference to “about” a value or parameter herein includes (and describes) variations that are directed to that value or parameter per se. For example, description referring to “about X” includes description of “X”.
- The terms “a” or “an,” as used in herein means one or more, unless the context clearly indicates otherwise.
- By “subject,” “individual,” or “patient” is meant an individual organism, preferably a vertebrate, more preferably a mammal, most preferably a human.
- The description is intended to embrace all salts of the compounds described herein, as well as methods of using such salts of the compounds. In one embodiment, the salts of the compounds comprise pharmaceutically acceptable salts. Pharmaceutically acceptable salts are those salts which can be administered as drugs or pharmaceuticals to humans and/or animals and which, upon administration, retain at least some of the biological activity of the free compound (neutral compound or non-salt compound). The desired salt of a basic compound may be prepared by methods known to those of skill in the art by treating the compound with an acid. Examples of inorganic acids include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid. Examples of organic acids include, but are not limited to, formic acid, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, sulfonic acids, and salicylic acid. Salts of basic compounds with amino acids, such as aspartate salts and glutamate salts, can also be prepared. The desired salt of an acidic compound can be prepared by methods known to those of skill in the art by treating the compound with a base. Examples of inorganic salts of acid compounds include, but are not limited to, alkali metal and alkaline earth salts, such as sodium salts, potassium salts, magnesium salts, and calcium salts; ammonium salts; and aluminum salts. Examples of organic salts of acid compounds include, but are not limited to, procaine, dibenzylamine, N-ethylpiperidine, N,N′-dibenzylethylenediamine, and triethylamine salts. Salts of acidic compounds with amino acids, such as lysine salts, can also be prepared. For lists of pharmaceutically acceptable salts, see, for example, P. H. Stahl and C. G. Wermuth (eds.) “Handbook of Pharmaceutical Salts, Properties, Selection and Use” Wiley-VCH, 2011 (ISBN: 978-3-90639-051-2). Several pharmaceutically acceptable salts are also disclosed in Berge, J. Pharm. Sci. 66:1 (1977).
- The phrase “therapeutically effective amount” as used herein means that amount of a compound, material, or formulation comprising a compound of the present invention which is effective for producing some desired therapeutic effect by inhibition of a T-Channel in at least a sub-population of cells in an animal, thereby blocking or lessening the biological consequences of that pathway in the treated cells, at a reasonable benefit/risk ratio applicable to any medical treatment.
- In an exemplary embodiment, the invention provides a method for treating a condition described herein in a mammal, the method comprises administering to the mammal a therapeutically effective amount of a compound described herein, or a compound according to a formula described herein, or a pharmaceutically acceptable salt thereof, sufficient to treat the condition, thereby treating the condition. In an exemplary embodiment, according to any method described herein, the mammal is in need of treatment with the compound. In an exemplary embodiment, according to any method described herein, the mammal is a dog, a cat, a horse, a pig, a cow, a sheep, a mouse, a guinea pig, or a rat. In an exemplary embodiment, according to any method described herein, the mammal is a human.
- In an exemplary embodiment, the invention provides a method for treating a condition described herein in a mammal, the method comprises administering to the mammal a therapeutically effective amount of a pharmaceutical formulation described herein, sufficient to treat the condition, thereby treating the condition. In an exemplary embodiment, according to any method described herein, the mammal is in need of treatment with the pharmaceutical formulation. In an exemplary embodiment, according to any method described herein, the mammal is not otherwise in need of treatment with the pharmaceutical formulation. In an exemplary embodiment, according to any method described herein, the mammal is a mouse or a rat. In an exemplary embodiment, according to any method described herein, the mammal is a human.
- The term “IC50” refers to the concentration causing a 50% inhibition of the specific binding of the control substance.
- The following abbreviations may be used herein:
-
- ˜ about
- +ve or pos. ion positive ion
- Δ heat
- Ac Acetyl
- can acetonitrile
- Ac2O acetic anhydride
- Aq aqueous
- AcOH acetic acid
- Bn benzyl
- Boc tert-butyloxycarbonyl
- BOP-C1 Bis(2-oxo-3-oxazolidinyl)phosphinic chloride
- BSA bovine serum albumin
- Bu butyl
- Bz benzoyl
- Calcd or Calc'd calculated
- Cbz carboxybenzyloxy, benzylcarbamate
- Conc. concentrated
- □ NMR, chemical shift in parts per million (ppm)
- D day(s) or doublet (NMR)
- DBU 1,8-diazabicyclo[5.4.0]undec-7-ene
- DCE dichloroethane
- DCM dichloromethane
- DDQ 2,3-dichloro-5,6-dicyano-1,4-benzoquinone
- DEA diethylamine
- DIEA or DIPEA diisopropylethylamine
- DMAP 4-dimethylaminopyridine
- DME 1,2-dimethoxyethane
- DMF N,N-dimethylformamide
- DMP Dess-Martin periodinane; 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxo1-3(1H)-one
- DMSO dimethyl sulfoxide
- DPPA Diphenylphosphoryl azide
- DRG Dorsal Root Ganglion
- EDC or EDCI N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide
- EGTA ethylene glycol tetraacetic acid
- Eq equivalent
- ESI or ES electrospray ionization
- Et ethyl
- Et2 O diethyl ether
- Et3 N triethylamine
- EtOAc ethyl acetate
- EtOH ethyl alcohol
- G gram(s)
- H hour(s)
- HATU O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate
- HBTU O-benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluorophosphate
- HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
- Hex hexanes
- HMPA hexamethylphosphoramide
- HOAt 1-hydroxy-7-azabenzotriazole
- HOBT hydroxybenzotriazole
- HPLC high pressure liquid chromatography
- IPA or iPrOH isopropyl alcohol
- KOAc potassium acetate
- LCMS, LC-MS or LC/MS liquid chromatography mass spectrometry
- LDA lithium diisopropylamide
- LHMDS or LiHMDS lithium hexamethyldisilazide
- M molar (mol L−1)
- Me methyl
- MeCN acetonitrile
- MeI iodomethane
- MeOH methyl alcohol
- Mg milligram(s)
- min minute(s)
- mL milliliter(s)
- M mole(s)
- MS mass spectrometry
- MsCl methanesulfonyl chloride
- MTBE or MtBE methyl tert-butyl ether
- m/z mass-to-charge ratio
- NaHMDS sodium hexamethyldisilazide
- NaOtBu sodium tert-butoxide
- NBS N-bromosuccinimide
- nBuLi n-butyl lithium
- NMO N-methylmorpholine-N-oxide
- NMP 1-methyl-2-pyrrolidinone
- NMR nuclear magnetic resonance
- PBS phosphate buffered saline
- PMB paramethoxybenzyl
- Pr propyl
- Prep-HPLC Preparative high pressure liquid chromatography
- Ppm parts per million
- p-tol para-toluoyl
- PTZ pentylenetetrazole
- Rac racemic
- RP-HPLC or RPHPLC reversed phase high pressure liquid chromatography
- RT or rt or r.t. room temperature
- sat or sat'd or satd Saturated
- SNI Spared nerve injury
- SNL Spinal nerve ligation
- TBAF tetrabutylammonium fluoride
- TBDMS tert-butyldimethylsilyl
- TBDMS-Cl tert-butyldimethylsilyl chloride
- TBDPS tert-butyldiphenylsilyl
- TEMPO (2,2,6,6-tetramethylpiperidin-1-yl)oxidanyl
- tert or t tertiary
- TFA or TFAA triflouroacetic acid
- THF tetrahydrofuran
- TLC thin layer chromatography
- TMS trimethylsilyl or trimethylsilane
- tR retention time
- tBuOH tert-butyl alcohol
- v/v volume per volume
- In one aspect the invention provides a compound of the invention. In an exemplary embodiment, the invention provides a compound described herein, or a salt thereof. In an exemplary embodiment, the salt of a compound described herein is a pharmaceutically acceptable salt. In an exemplary embodiment, the invention provides a compound described herein, or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the invention provides a compound described in a formula provided herein. In an exemplary embodiment, the invention provides a compound described herein. One object of the present invention is to provide a compound, or a pharmaceutically acceptable salt thereof, which can be used to treat chronic cough or itching, of the general structure:
-
- I) wherein R1 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; X is selected from —N(R14)—C(═O)—, or —N(R14)—S(═O)k—, or —CH2—N(R14)—C(═O) —, or —CH2—N(R14)—S(═O)k—, or C(═O)—N(R14), and —CH2—C(═O)—N(R14), or CH2—N(R14); k is selected from 1 and 2; and R14 is H or substituted or unsubstituted C1-C6 alkyl or substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heteroalkyl; R2 is selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl; R3, R4, R5, R6 are each independently hydrogen, substituted or unsubstituted —C1-6 alkyl, substituted or unsubstituted —C1-6 haloalkyl, a 3-, 4-, 5- or 6-membered substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl group, wherein R3 and R4 along with the carbon to which they are attached optionally form a 3- to 6-membered substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl group, said heterocycloalkyl group optionally containing 1 or 2 heteroatoms independently selected from O, N or S, and said substituted cycloalkyl or substituted heterocycloalkyl group is optionally substituted with 1, 2, or 3 substituents independently selected from F, —C1-6 alkyl, and —CF3. R5 and R6, together with the carbon to which they are attached, optionally form a 3—, 4-, 5- or 6-membered substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl group, said heterocycloalkyl group optionally containing 1 or 2 heteroatoms independently selected from O, N or S, and said cycloalkyl or heterocycloalkyl group is optionally substituted with from 1, 2 or 3 substituents independently selected from F, —C1-6 alkyl, and —CF3. R7, R8, R9, and R10 are each independently hydrogen, fluorine, substituted or unsubstituted-C1-6 alkyl, substituted or unsubstituted-C1-6 haloalkyl, a 3—, 4-, 5- or 6-membered substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl group, wherein R7 and R8, together with the carbon to which they are attached, optionally form a 3-, 4-, 5-, or 6-membered substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl group, said heterocycloalkyl group optionally containing 1 or 2 heteroatoms independently selected from O, N or S, and said substituted cycloalkyl or substituted heterocycloalkyl group is optionally substituted with 1, 2 or 3 substituents independently selected from F, —C1-6 alkyl, or —CF3; R9 and R10, together with the carbon to which they are attached, optionally form a 3—, 4-, 5- or 6-membered substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl group, said heterocycloalkyl group containing from 1 or 2 heteroatoms independently selected from O, N or S, and the substituted cycloalkyl or substituted heterocycloalkyl group is optionally substituted with 1, 2, or 3 substituents independently selected from F, —C1-6 alkyl, or —CF3; R11, R12 and R3 are each independently hydrogen, fluorine, substituted or unsubstituted-C1-6 alkyl, substituted or unsubstituted-C1-6 haloalkyl, a 3-, 4-, 5- or 6-membered substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl group, wherein R11 and either R1 or R13, together with the carbons to which they are attached, optionally form a 3-, 4-, 5-, 6-or 7-membered substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl group.
- In an exemplary embodiment, wherein R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and X are as described herein, R1 is selected from substituted or unsubstituted benzyl or a substituted or unsubstituted polycyclic cycloalkyl ring, e.g., adamantyl. In an exemplary embodiment, wherein R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and X are as described herein, R1 is substituted adamantyl. In an exemplary embodiment, wherein R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and X are as described herein, R1 is substituted adamant-1-yl. In an exemplary embodiment, wherein R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and X are as described herein, R1 is unsubstituted adamantyl. In an exemplary embodiment, wherein R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and X are as described herein, R1 is unsubstituted adamant-l-yl.In an exemplary embodiment, wherein R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and X are as described herein, R1 is substituted by 1, 2, 3 or 4 non-hydrogen substituents selected from halo, haloalkyl, substituted or unsubstituted alkoxy, and cyano.
- In an exemplary embodiment, the compounds of the invention used to treat chronic cough or itching have a structure according to Formula I, wherein R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and X are as described herein, R1 is of the formula:
- wherein A, B, C and D are independently selected from “aryl group substituents”; and the indices a, b, c, and d are independently selected from 0 and 1.
- In an exemplary embodiment, the compounds of the invention used to treat chronic cough or itching have a structure according to Formula I, wherein R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and X are as described herein, A, B, C and D are independently selected from CN, Cl, Br, F, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 heteroalkyl, substituted or unsubstituted C1-C6 haloalkyl, and substituted or unsubstituted C1-C6 alkoxy.
- In an exemplary embodiment, wherein RI, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and X are as described herein, R2 is selected from C1-C10 straight chain or branched substituted or unsubstituted C1-C6 alkyl, and C1-C10 substituted or unsubstituted C1-C6 alkyl heteroalkyl. In an exemplary embodiment, wherein R1, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and X are as described herein, R2 includes substituted alkyl or substituted heteroalkyl groups, which are substituted with amide, oxo, substituted or unsubstituted aryl or substituted or unsubstituted heterocycloalkyl. Exemplary substituted aryl groups include substituted or unsubstituted phenyl, and an exemplary heterocycloalkyl moiety is an oxygen-containing heterocycle.
- In an exemplary embodiment, a compound of the invention used to treat chronic cough or itching has the formula:
- wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11a, R11b, and X are as described herein, wherein q is an integer selected from 1, 2, 3, 4 and 5. In an exemplary embodiment, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and X are as described herein, wherein R11 and R11b are members each independently selected from H, methyl, and fluorine. In an exemplary embodiment, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and X are as described herein, q is 1, R11a is H and R11b is F. In an exemplary embodiment, wherein RI, R2, R3, R4, R5, R6, R7, R8, R9, R10, and X are as described herein, q is 1, R11a is F and R11b is F.
- In an exemplary embodiment, a compound of the invention used to treat chronic cough or itching has the formula:
- wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and X are as described herein, q is an integer selected from 1, 2, 3, 4 and 5.
- In an exemplary embodiment, a compound of the invention used to treat chronic cough or itching has the formula:
- wherein X, R2, and R2 are as described herein, and q is 1 or 2.
- In an exemplary embodiment, a compound of the invention used to treat chronic cough or itching has the formula:
- wherein X, R2, and R2 are as described herein, and q is 1 or 2.
- In an exemplary embodiment, a compound of the invention used to treat chronic cough or itching has the formula:
- wherein X, R2, and R2 are as described herein, and q is 1 or 2.
- In an exemplary embodiment, a compound of the invention used to treat chronic cough or itching has the formula:
- wherein X, R2, and R2 are as described herein, and q is 1 or 2.
- 100911 In an exemplary embodiment, a compound of the invention used to treat chronic cough or itching has the formula:
- wherein X, R1, and R2 are as described herein, and q is 1 or 2.
- In an exemplary embodiment, wherein q, R2, R3, R4, R5, R6, R7, R8, R9, RI° , and X are as described herein, wherein R1 is substituted or unsubstituted benzyl or substituted or unsubstituted adamantyl. In an exemplary embodiment, wherein q, R2, R3, R4, R5, R6, R7, R8, R9, R10, and X are as described herein, wherein Ri is substituted phenyl. In an exemplary embodiment, wherein q, R2, R3, R4, R5, R6, R7, R8, R9, R10, and X are as described herein, wherein R1 is unsubstituted phenyl. In an exemplary embodiment, wherein q, R2, R3, R4, R5, R6, R7, R8, R9, R10, and X are as described herein, wherein Ri is substituted or unsubstituted adamantyl. In an exemplary embodiment, wherein q, R2, R3, R4, R5, R6, R7, R8, R9, R10, and X are as described herein, wherein R1 is
- wherein
- represents the covalent link between R1 and X; and R1a and R1b are members each independently selected from halo, haloalkyl, substituted or unsubstituted alkoxy, and cyano. In an exemplary embodiment, wherein q, R2, R3, R4, R5, R6, R7, R8, R9, R10, and X are as described herein, wherein R1 is
- In an exemplary embodiment, wherein q, R2, R3, R4, R5, R6, R7, R8, R9, R10, and X are as described herein, wherein R2 is substituted or unsubstituted alkyl. In an exemplary embodiment, wherein q, R2, R3, R4, R5, R6, R7, R8, R9, R10, and X are as described herein, wherein R2 is substituted or unsubstituted heteroalkyl. In an exemplary embodiment, wherein q, R2, R3, R4, R5, R6, R7, R8, R9, R10, and X are as described herein, wherein R2 is
- In an exemplary embodiment, the compound used to treat chronic cough or itching has the following formula:
- wherein X, R2, and R1 are as described herein.
- In an exemplary embodiment, the compound used to treat
- chronic cough or itching has the following formula:
- wherein X, R2, and R1 are as described herein. In an exemplary embodiment, the compound is according to a formula described herein, and R1 is phenyl substituted with one to three substituents, each of which is a member selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is according to a formula described herein, and R1 is phenyl substituted with one substituent which is a member selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is according to a formula described herein, and R2 is phenyl substituted with two substituents which are members each individually selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is according to a formula described herein, and R2 is phenyl substituted with thee substituents which are members each individually selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound has the following formula:
- wherein X, R2, and R1 are as described herein. In an exemplary embodiment, the compound has the following formula:
- wherein, X, R2, and R1 are as described herein.
- In an exemplary embodiment, the compound used to treat chronic cough or itching is
- wherein X and R1 are as described herein. In an exemplary embodiment, the compound is
- wherein X and R1 are as described herein. In an exemplary embodiment, the compound is
- wherein X and R1 are as described herein. In an exemplary embodiment, the compound is
- wherein X and R1 are as described herein. In an exemplary embodiment, the compound is
- wherein X and R1 are as described herein. In an exemplary embodiment, the compound is
- wherein X and R1 are as described herein.
- In an exemplary embodiment, the compound is
- wherein R1 and R2 are as described herein. In an exemplary embodiment, the compound is
- wherein R1 and R2 are as described herein. In an exemplary embodiment, the compound is
- wherein R1 and R2 are as described herein. In an exemplary embodiment, the compound is
- wherein R1 and R2 are as described herein. In an exemplary embodiment, the compound is
- wherein R1 and R2 are as described herein. In an exemplary embodiment, the compound is
- wherein R1 and R2 are as described herein.
- In an exemplary embodiment, the compound is
- wherein X and R2 are as described herein, R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3.
- In an exemplary embodiment, the compound is
- wherein X and R2 are as described herein, R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3.
- In an exemplary embodiment, the compound is
- wherein X and R2 are as described herein, R1 is as described herein. In an exemplary embodiment, the compound is
- wherein X and R2 are as described herein, R1 is unsubstituted adamantyl. In an exemplary embodiment, the compound is
- wherein X and R2 are as described herein, R1 is unsubstituted adamant-1-yl.
- In an exemplary embodiment, the compound is
- wherein R2, R1a and R1b are as described herein. In an exemplary embodiment, the compound is according to a formula described herein which contains R1a and R1b, wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is according to a formula described herein which contains R1 a and R1b, wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is according to a formula described herein which contains R1a and R1b, wherein R1a is as described herein, and R1b is F. In an exemplary embodiment, the compound is according to a formula described herein which contains R1a and R1b, wherein R1a is as described herein, and R1b is Cl. In an exemplary embodiment, the compound is according to a formula described herein which contains R1a and R1b, wherein R1a is as described herein, and R1b is CF3. In an exemplary embodiment, the compound is according to a formula described herein which contains R1a and R1b, wherein R1b is as described herein, and R1a is F. In an exemplary embodiment, the compound is according to a formula described herein which contains R1a and R1b, wherein R1b is as described herein, and R1a is Cl. In an exemplary embodiment, the compound is according to a formula described herein which contains R1a and R1b, wherein R1b is as described herein, and R1a is CF3. In an exemplary embodiment, the compound is
- wherein R2, R1a and R1b are as described herein. In an exemplary embodiment, the compound is
- wherein R2, R1a and R1b are as described herein. In an exemplary embodiment, the compound is
- wherein R2, R1a and R1b are as described herein. In an exemplary embodiment, the compound is
- wherein R2, R1a and R1b are as described herein. In an exemplary embodiment, the compound is
- wherein R2, R1a and R1b are as described herein.
- In an exemplary embodiment, the compound is
- wherein R2, R1a and R1b are as described herein. In an exemplary embodiment, the compound is according to a formula described herein which contains R1a and R1b, wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is according to a formula described herein which contains R1 a and R1b, wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is according to a formula described herein which contains R1a and R1b, wherein R1a is as described herein, and R1b is F. In an exemplary embodiment, the compound is according to a formula described herein which contains R1a and R1b, wherein R1a is as described herein, and R1b is Cl. In an exemplary embodiment, the compound is according to a formula described herein which contains R1a and R1b, wherein R1a is as described herein, and R1b is CF3. In an exemplary embodiment, the compound is according to a formula described herein which contains R1a and R1b, wherein R1b is as described herein, and R1a is F. In an exemplary embodiment, the compound is according to a formula described herein which contains R1 a and R1b, wherein R1b is as described herein, and Ria is Cl. In an exemplary embodiment, the compound is according to a formula described herein which contains R1a and R1b, wherein R1bis as described herein, and R1a is CF3. In an exemplary embodiment, the compound is
- wherein R2, R1a and R1b are as described herein. In an exemplary embodiment, the compound is
- wherein R2, R1a and R1b are as described herein. In an exemplary embodiment, the compound is
- wherein R2, R1a and R1b are as described herein. In an exemplary embodiment, the compound is
- wherein R2, R1a and R1b are as described herein. In an exemplary embodiment, the compound is
- wherein R2, R1a and R1b are as described herein.
- In an exemplary embodiment, the compound is
- wherein wherein R2 is as described herein, and R1 is unsubstituted adamantyl. In an exemplary embodiment, the compound is
- wherein R2 is as described herein, and R1 is unsubstituted adamant-1-yl. In an exemplary embodiment, the compound is
- wherein R2 is as described herein, and R1 is unsubstituted adamantyl. In an exemplary embodiment, the compound is
- wherein R2 is as described herein, and R1 is unsubstituted adamant-1-yl. In an exemplary embodiment, the compound is
- wherein R2 is as described herein, and R1 is unsubstituted adamantyl. In an exemplary embodiment, the compound is
- wherein R2 is as described herein, and R1 is unsubstituted adamant-1-yl.
- In an exemplary embodiment, the compound is
- wherein R1 is as described herein. In an exemplary embodiment, the compound is
- wherein R1 is as described herein. In an exemplary embodiment, the compound is
- wherein R1 is as described herein. In an exemplary embodiment, the compound is
- wherein R1 is as described herein. In an exemplary embodiment, the compound is
- wherein R1 is as described herein. In an exemplary embodiment, the compound is
- wherein R1 is as described herein. In an exemplary embodiment, the compound is
- wherein R1 is as described herein. In an exemplary embodiment, the compound is
- wherein R1 is as described herein. In an exemplary embodiment, the compound is
- wherein R1 is as described herein. In an exemplary embodiment, the compound is
- wherein R1 is as described herein. In an exemplary embodiment, the compound is
- wherein R1 is as described herein. In an exemplary embodiment, the compound is
- wherein R1 is as described herein.
- In an exemplary embodiment, the compound is
- wherein X, R1a and R1b are as described herein. In an exemplary embodiment, the compound is
- wherein X, R1a and R1b are as described herein. In an exemplary embodiment, the compound is
- wherein X, R1a and R1b are as described herein. In an exemplary embodiment, the compound is
- wherein X, R1a and R1b are as described herein. In an exemplary embodiment, the compound is
- wherein X, R1a and R1b are as described herein. In an exemplary embodiment, the compound is
- wherein X, R1a and R1b are as described herein.
- In an exemplary embodiment, the compound is
- wherein X is as described herein, and R1 is unsubstituted adamantyl. In an exemplary embodiment, the compound is
- wherein X is as described herein, and R1 is unsubstituted adamant-1-yl. In an exemplary embodiment, the compound is
- wherein X is as described herein, and R1 is unsubstituted adamantyl. In an exemplary embodiment, the compound is
- wherein X is as described herein, and R1 is unsubstituted adamant-1-yl. In an exemplary embodiment, the compound is
- wherein X is as described herein, and R1 is unsubstituted adamantyl. In an exemplary embodiment, the compound is
- wherein X is as described herein, and R1 is unsubstituted adamant-1-yl. In an exemplary embodiment, the compound is
- wherein X is as described herein, and R1 is unsubstituted adamantyl. In an exemplary embodiment, the compound is
- wherein X is as described herein, and R1 is unsubstituted adamant-1-yl. In an exemplary embodiment, the compound is
- wherein X is as described herein, and R1 is unsubstituted adamantyl. In an exemplary embodiment, the compound is
- wherein X is as described herein, and R1 is unsubstituted adamant-1-yl. In an exemplary embodiment, the compound is
- wherein X is as described herein, and R1 is unsubstituted adamantyl. In an exemplary embodiment, the compound is
- wherein X is as described herein, and R1 is unsubstituted adamant-1-yl.
- In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3.
- In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3. In an exemplary embodiment, the compound is
- wherein R1a and R1b are members each independently selected from the group consisting of F, Cl, and CF3.
- In an exemplary embodiment, the compound is
- wherein R1 is unsubstituted adamantyl. In an exemplary embodiment, the compound is
- wherein R1 is unsubstituted adamant-1-yl. In an exemplary embodiment, the compound is
- wherein R1 is unsubstituted adamantyl. In an exemplary embodiment, the compound is
- wherein R1 is unsubstituted adamant-1-yl. In an exemplary embodiment, the compound is
- wherein R1 is unsubstituted adamantyl. In an exemplary embodiment, the compound is
- wherein R1 is unsubstituted adamant-1-yl. In an exemplary embodiment, the compound is
- wherein R1 is unsubstituted adamantyl. In an exemplary embodiment, the compound is
- wherein R1 is unsubstituted adamant-1-yl.
In an exemplary embodiment, the compound is - wherein R1 is unsubstituted adamantyl. In an exemplary embodiment, the compound is
- wherein R1 is unsubstituted adamant-1-yl.
In an exemplary embodiment, the compound is - wherein R1 is unsubstituted adamantyl.
- In an exemplary embodiment, the compound is
- wherein R1 is unsubstituted adamant-1-yl.
In an exemplary embodiment, the compound is - wherein R1 is unsubstituted adamantyl. In an exemplary embodiment, the compound is
- wherein R1 is unsubstituted adamant-1-yl. In an exemplary embodiment, the compound is
- wherein R1 is unsubstituted adamantyl. In an exemplary embodiment, the compound is
- wherein R1 is unsubstituted adamant-1-yl.
In an exemplary embodiment, the compound is - wherein R1 is unsubstituted adamantyl.
In an exemplary embodiment, the compound is - wherein R1 is unsubstituted adamant-1-yl. In an exemplary embodiment, the compound is
- wherein R1 is unsubstituted adamantyl. In an exemplary embodiment, the compound is
- wherein R1 is unsubstituted adamant-1-yl. In an exemplary embodiment, the compound is
- wherein R1 is unsubstituted adamantyl. In an exemplary embodiment, the compound is
- wherein R1 is unsubstituted adamant-1-yl. In an exemplary embodiment, the compound is
- wherein R1 is unsubstituted adamantyl. In an exemplary embodiment, the compound is
- wherein R1 is unsubstituted adamant-1-yl.
- In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof.
- In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof.
- In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof.
- In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof.
- In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof.
- In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof.
- In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof.
- In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof.
- In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof.
- In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof, wherein R1 is unsubstituted adamant-1-yl. In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof, wherein R1 is unsubstituted adamant-1-yl. In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof, wherein R1 is unsubstituted adamant-1-yl.
- In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the compound is
- or a pharmaceutically acceptable salt thereof
- In one exemplary embodiment, the structure of AFA-358 is
- In one exemplary embodiment, the structure of AFA-309 is
- In one exemplary embodiment, the structure of AFA-258 is
- In one exemplary embodiment, the structure of AFA-353 is
- AFA-309, 353 and 358 are novel T-type Ca v a channel modulators used in the treatment of pathological conditions, including pain, hypersensitive cough and itching.
- The invention also provides a pharmaceutical formulation comprising a therapeutically effective amount of a compound according to Formula I or individually disclosed herein. The formulation further includes a pharmaceutically acceptable carrier. The invention also provides a method for treating hypersensitive cough or ticking responsive to selective inhibition of the T Channel known as the Cav3.2 channel comprising administering to a mammal a therapeutically effective amount of a compound according to Formula I or individually disclosed herein.The present invention provides compounds which are selective T-Channel inhibitory compounds useful for relief of hypersensitive cough or itching.
- The invention also includes, where chemically possible, all stereoisomers and geometric isomers of the compounds, including diastereomers, enantiomers, and cis/trans (E/Z) isomers. The invention also includes mixtures of stereoisomers and/or geometric isomers in any ratio, including, but not limited to, racemic mixtures. Unless stereochemistry is explicitly indicated in a structure, the structure is intended to embrace all possible stereoisomers of the compound depicted. If stereochemistry is explicitly indicated for one portion or portions of a molecule, but not for another portion or portions of a molecule, the structure is intended to embrace all possible stereoisomers for the portion or portions where stereochemistry is not explicitly indicated.
- The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (3H) , iodine-125 (125I) or carbon-14 (14C) All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention. Unless a specific isotope is indicated, the invention includes all isotopologues of the compounds disclosed herein, such as, for example, deuterated derivatives of the compounds (where H can be 2H, i.e., D).
- In the context of the present invention, compounds that are considered to possess activity as T-Channel inhibitors are those displaying 50% inhibition of the Ca++ voltage (IC50) at a concentration of not higher than about 100 □M, preferably, not higher than about 10 □M, more preferably not higher than about 1 □M and most preferably not higher than about 100 nM.
- Terminology related to “protecting”, “deprotecting” and “protected” functionalities occurs throughout this application. Such terminology is well understood by persons of skill in the art and is used in the context of processes that involve sequential treatment with a series of reagents. In that context, a protecting group refers to a group which is used to mask a functionality during a process step in which it would otherwise react, but in which reaction is undesirable. The protecting group prevents reaction at that step, but may be subsequently removed to expose the original functionality. The removal or “deprotection” occurs after the completion of the reaction or reactions in which the functionality would interfere. Thus, when a sequence of reagents is specified, as it is in the processes of the invention, the person of ordinary skill can readily envision those groups that would be suitable as “protecting groups”. Suitable groups for that purpose are discussed in standard textbooks in the field of chemistry, such as “Greene's Protective Groups in Organic Synthesis: Fifth Edition” by Peter G. M. Wuts, [John Wiley & Sons, New York, 2014], DOI: 10.1002/9781118905074, which is incorporated herein by reference.
- A comprehensive list of abbreviations utilized by organic chemists appears in the first issue of each volume of the Journal of Organic Chemistry. The list, which is typically presented in a table entitled “Standard List of Abbreviations”, is incorporated herein by reference.
- In general, the compounds of the present invention may be prepared by the methods illustrated in the general reaction schemes as, for example, described below, or by modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants that are in themselves known, but are not mentioned here. The starting materials, for example in the case of suitably substituted benzimidazole ring compounds, are either commercially available, synthesized as described in the examples or may be obtained by the methods well known to persons of skill in the art.
- The present invention further provides pharmaceutical formulations comprising as active agents, the compounds described herein.
- In an exemplary embodiment, the invention is a pharmaceutical formulation comprising a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof. In an exemplary embodiment, the invention is a pharmaceutical formulation comprising a therapeutically effective amount of a compound of a formula described herein, or a pharmaceutically acceptable salt thereof.
- In an exemplary embodiment, the invention is a pharmaceutical formulation comprising a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In an exemplary embodiment, the invention is a pharmaceutical formulation comprising a therapeutically effective amount of a compound of a formula described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- In an exemplary embodiment, the invention is a pharmaceutical formulation described herein, wherein the formulation is in a unit dosage form.
- As used herein a “pharmaceutical formulation” refers to a preparation of one or more of the compounds described herein, or physiologically acceptable salts or solvates (including hydrates) thereof, with other chemical components such as physiologically suitable carriers and excipients.
- Pharmaceutical formulations containing compounds of Formulas I, and. any compound described herein may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy. Preferred unit dosage formulations are those containing an effective dose, or an appropriate fraction thereof, of the active ingredient, or a pharmaceutically acceptable salt thereof. The magnitude of a prophylactic or therapeutic dose typically varies with the nature and severity of the condition to be treated and the route of administration. The dose, and perhaps the dose frequency, will also vary according to the age, body weight and response of the individual patient. In general, a dose ranges from about mg to about 7000 mg, preferably about 1 mg to about 100 mg, and more preferably, about 25 mg to about 50 mg, in single or divided doses. In some embodiments, a dose may range from about mg to about 500 mg, and preferably, about 100 mg to about 500 mg. Such doses may be administered 1, 2, 3, 4, 5, 6 or more times in a day. It may be recommended that children, patients over 65 years old, and those with impaired renal or hepatic function, initially receive low doses and that the dosage is titrated based on individual responses and/or blood levels. It may be necessary to use dosages outside these ranges in some cases, as will be apparent to those in the art. Further, it is noted that the clinician or treating physician knows how and when to interrupt, adjust or terminate therapy in conjunction with individual patient's response.
- Pharmaceutical formulations for use in accordance with the present invention thus may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active compounds into preparations which, can be used pharmaceutically. The carriers must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Proper formulation is dependent upon the route of administration chosen.
- Compounds that inhibit T-Channels can be formulated as pharmaceutical formulations and administered to a mammalian subject, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., oral, rectal, topical (including dermal, buccal, sublingual, and intraocular), or parenteral, by intravenous, intramuscular, topical, transdermal, intradermal, intraarticular, or subcutaneous routes.
- For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient. Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carbomethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar or alginic acid or a salt thereof such as sodium alginate.
- In addition, an enteric coating may be useful as it is may be desirable to prevent exposure of the compounds of the invention to the gastric environment.
- Pharmaceutical formulations, which can be used orally, include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added.
- Formulations for topical administration in the mouth, for example buccally or sublingually, include lozenges comprising the active ingredient in a flavored basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia. All formulations for oral administration should be in dosages suitable for the chosen route of administration.
- For injection, the compounds of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's or Ringer's solution or physiological saline buffer. For transmucosal and transdermal administration, penetrants appropriate to the barrier to be permeated may be used in the formulation. Such penetrants, including for example DMSO or polyethylene glycol, are known in the art.
- For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
- Pharmaceutical formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions, which may contain anti-oxidants, buffers, bacteriostats and solutes, which render the formulation isotonic with the blood of the intended recipient. Formulations also include aqueous and non-aqueous sterile suspensions, which may include suspending agents and thickening agents. Pharmaceutical formulations for parenteral administration in an aqueous solution contain the active ingredients in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents, which increase the solubility of the compounds, to allow for the preparation of highly concentrated solutions.
- The formulations may be presented in unit-dose of multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of a sterile liquid carrier, for example saline, phosphate-buffered saline (PBS) or the like, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- The compounds of the present invention may also be formulated in rectal formulations such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.
- Depending on the severity and responsiveness of the condition to be treated, dosing can also be a single administration of a slow release formulations, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved. The amount of a formulation to be administered will, of course, be dependent on many factors including the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician. The compounds of the invention may be administered orally or via injection at a dose from 0.001 to 250 mg/kg per day. The dose range for adult humans is generally from 0.5 mg to 10 g/day. Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of compound of the invention which is effective at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually around 10 mg to 200 mg. The precise amount of compound administered to a patient will be the responsibility of the attendant physician. However, the dose employed will depend on a number of factors, including the age and sex of the patient, the precise disorder being treated, and its severity. Also, the route of administration may vary depending on the condition and its severity.
- As used herein, and as would be understood by the person of skill in the art, the recitation of “a compound” is intended to include salts, solvates and inclusion complexes of that compound. The term “solvate” refers to a compound described herein and/or from Formula I in the solid state, wherein molecules of a suitable solvent are incorporated in the crystal lattice. A suitable solvent for therapeutic administration is physiologically tolerable at the dosage administered. Examples of suitable solvents for therapeutic administration are ethanol and water. When water is the solvent, the solvate is referred to as a hydrate. In general, solvates are formed by dissolving the compound in the appropriate solvent and isolating the solvate by cooling or using an antisolvent. The solvate is typically dried or azeotroped under ambient conditions. Inclusion complexes are described in Remington: The Science and Practice of Pharmacy 19th Ed. (1995) volume 1, page 176—177, which is incorporated herein by reference. The most commonly employed inclusion complexes are those with cyclodextrins, and all cyclodextrin complexes, natural and synthetic, are specifically encompassed within the claims.
- The term “pharmaceutically acceptable salt” refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids and bases and organic acids and bases. When the compounds of the present invention are basic, salts may be prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids. Suitable pharmaceutically acceptable acid addition salts for the compounds of the present invention include acetic, benzenesulfonic (besylate), benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric acid, p-toluenesulfonic, and the like. When the compounds contain an acidic side chain, suitable pharmaceutically acceptable base addition salts for the compounds of the present invention include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.
- The term “preventing” as used herein refers to administering a medicament beforehand to forestall or obtund an attack. The person of ordinary skill in the medical art (to which the present method claims are directed) recognizes that the term “prevent” is not an absolute term. In the medical art it is understood to refer to the prophylactic administration of a drug to substantially diminish the likelihood or seriousness of a condition, and this is the sense intended herein.
- It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
- The formulations may be presented in a packaging device or dispenser, which may contain one or more unit dosage forms containing the active ingredient. Examples of a packaging device include metal or plastic foil, such as a blister pack and a nebulizer for inhalation. The packaging device or dispenser may be accompanied by instructions for administration. Formulations comprising a compound of the present invention formulated in a compatible pharmaceutical carrier may also be placed in an appropriate container and labeled for treatment of an indicated condition.
- Some embodiments described herein are recited as “comprising” or “comprises” with respect to their various elements. In alternative embodiments, those elements can be recited with the transitional phrase “consisting essentially of” or “consists essentially of” as applied to those elements. In further alternative embodiments, those elements can be recited with the transitional phrase “consisting of” or “consists of” as applied to those elements. Thus, for example, if a compound, formulation or method is disclosed herein as comprising A and B, the alternative embodiment for that compound, formulation or method of “consisting essentially of A and B” and the alternative embodiment for that compound, formulation or method of “consisting of A and B” are also considered to have been disclosed herein. Likewise, embodiments recited as “consisting essentially of” or “consisting of” with respect to their various elements can also be recited as “comprising” as applied to those elements. Finally, embodiments recited as “consisting essentially of” with respect to their various elements can also be recited as “consisting of” as applied to those elements, and embodiments recited as “consisting of” with respect to their various elements can also be recited as “consisting essentially of” as applied to those elements.
- When a compound or formulation is described as “consisting essentially of” the listed components, the compound or formulation contains the components expressly listed, and may contain other components which do not substantially affect the condition being treated. That is, the compound or formulation either does not contain any other components which do substantially affect the condition being treated other than those components expressly listed; or, if the compound or formulation does contain extra components other than those listed which substantially affect the condition being treated, the compound or formulation does not contain a sufficient concentration or amount of those extra components to substantially affect the condition being treated. When a method is described as “consisting essentially of” the listed steps, the method contains the steps listed, and may contain other steps that do not substantially affect the condition being treated, but the method does not contain any other steps which substantially affect the condition being treated other than those steps expressly listed.
- The following examples are provided to illustrate, but not limit, the invention. The compounds disclosed herein are numbered and proceeded by the prefix EX- or AFA-.
- Guinea pigs (male, 280 g body weight, Hartley Crl:HA, Charles River) were maintained in temperature 21±2° C., humidity 55±10%, 12 hours on-12 hours off light cycle, with food and water ad libitum for at least 1 week before testing. Cough was induced with citric acid aerosol inhalation and cough assessment by human manual score (Gallico, Borghi et al. 1994). Individual animals were placed in a 4L plexiglas observation chambers continuously filled with 17.5% citric acid aerosol. Animal cough counts were recorded for 5 min. Coughs can be recognized on the basis of sound associated with a rapid inspiration followed by a rapid expiration. Only the animal with cough counts >=10 times/5 min was selected for experiment. The selected animal was then randomized divided into 5 groups, n=8/group. Five days after screening test, the representative AFA-compound, EX-17 at 3, 10 and 30 mg/kg were administered 30 minutes while the benchmark dextromethorphan hydrobromide (60 mg/kg, p.o.) 60 minutes prior to the citric acid inhalation, based on their PK profiles. EX-17 produced a dose-dependent inhibition of the number of cough events with reduction of 7.2, 23.3 and 36.8% at dose of 3, 10 and 30 mg/kg, respectively (
FIG. 1A ). At 30 mg/kg EX-17 produced comparable inhibition as dextromethorphan (40.0% at 60 mg/kg, p.o.). The latency to the first cough has been used as an additional parameter to evaluate antitussive property. EX-17 also caused increases in the latencies of the first cough in a dose-dependent manner. Only at 30 mg/kg EX-17 and dextromethorphan hydrobromide (60 mg/kg, p.o.) reached significance under the experimental conditions (FIG. 1B ). - Using the same test protocol, three more representative EX-compounds EX-128, -130 and -132 (each 30 mg/kg, p.o.) or vehicle were tested by orally administering30 minutes while dextromethorphan hydrobromide (60 mg/kg, p.o.) 60 minutes prior to the citric acid inhalation, based on their PK profiles. Compared to the vehicle control, compounds EX-128 and dextromethorphan significantly reduced the number of cough events with reduction of 39.1% and 42.6%, respectively (
FIG. 2A ). EX-130 and -132 showed a trend towards reducing the number of cough events with reduction of 33% and 15.7, respectively, without reaching significance. The latencies to the first cough were increased with three compounds and the benchmark, but none of them reached significance level under the experimental conditions (FIG. 2B ). -
-
- Canning, B. J. and Chou, Y. L. (2004). “Cough Sensors. I. Physiological and Pharmacological Properties of the Afferent Nerves Regulating Cough” in “Pharmacology and Therapeutics of Cough” ed. Chung and Widdicomb, pp 23-47, Handbook of Experimental Pharmacology ISSN 0171-2004
- Gallico, L., A. Borghi, C. Dalla Rosa, R. Ceserani and S. Tognella (1994). “Moguisteine: a novel peripheral non-narcotic antitussive drug.” Br J Pharmacol 112(3): 795-800.
- Irwin, R. S., M. J. Rosen and S. S. Braman (1977). “Cough. A comprehensive review.” Arch Intern Med 137(9): 1186-1191.
- Kase, Y., Y. Wakita, G. Kito, T. Miyata, T. Yuizono and M. Kataoka (1970). “Centrally-induced coughs in the cat.” Life Sci 9(1): 49-59.
- North, R. A. (2016). “P2X receptors.” Philos Trans R Soc Lond B Biol Sci 371(1700).
- Pachuau, J, Martin-Caraballo, M. (2007). Expression pattern of T-type Ca(2+) channels in embryonic chick nodose ganglion neurons. Dev Neurobiol. 67(14):1901-14.
- A representative panel of AFA/EX compounds was investigated on a variety of recombinant human ion channels expressed in mammalian cells and on native ion channels in dissociated rat dorsal root ganglion (DRG) neurons. As shown in Table 1, the selected 10 AFA-compounds produced differential modulations on different ion currents mediated by the selected ion channels. Thus, this panel of compounds was next investigated on their effects on itching scratching behavior in two well-established itching models in mice.
- Neck model of itch was employed. Mice (C57BL/6, male, 3-4 months old) were shaved at the nape of the neck 2-3 days before experiments. On the day of behavioral testing mice were individually placed in small plastic chambers (12 cm L×9.5 W×12 H) that inserted into an ordinary homecage at least 30 min for habituation and recorded baseline of behavior using a video camera and a piezoelectric floor sensor operated by a validated homecage behavioral monitory system, SmartCage, which can monitor multiple mouse scratching behaviors simultaneously.
- Treatment with an individual test article (10 representative AFA-compounds, each at 30 mg/kg) or vehicle (0.5% hydroxyl propyl cellulose aqueous solution containing 2% DMSO) were intraperitoneally (i.p.) injected 30 min prior to itching induction. Mice were given an intradermal injection of 50 μl of a pruritogen, chloroquine or histamine into the nape of the neck. Immediately after the injection, mice were returned to their chambers and were continually recorded by the piezoelectric floor sensor for 30 min. Human manual scoring of itching scratch behavior in real-time and confirmed by video and/or piezoelectric recordings offline. The itch behavior was quantified by counting the number of scratches in a blinded to the treatment manner. A scratch was counted when a mouse lifted its hindpaw to scratch the shaved region and returned the paw to the floor or to the mouth for licking. The piezoelectric signals with a larger and regular waveform distinguished from normal homecage activity were analyzed off-line to objectively quantifying scratch episodes and durations.
- These studies revealed unexpected findings that compounds produced differential modulation of itch scratch behavior in these two different itching models despite those compounds with similar potency against T-type Cav3.2 channels (
FIG. 3A ). AFA-221 (EX-31), AFA-281 (EX-130) and AFA-358 produced potent and equal efficacy against both chloroquine- and histamine-induced itching, while AFA-309, AFA-258 (Z944), AFA-322 (EX-132) and AFA-206 (EX-55) preferentially inhibited histamine-induced itching (FIG. 3B ). - In conclusion, using an itching scratch behavior phenotypic analysis, one can discover novel compounds for potential treatment of chronic itch diseases.
-
TABLE 1 Effects of representative AFA Compounds on recombinant and native ion channels hCav3.2 Channel hCav2.2 hCav1.2 hiPSC INa hNav1.5 Inhibition of Currents in rat DRG hERG Compound IC50 μM % Use Dep. IC50 μM IC50 (μM) IC50 μM IC50 μM T IC50 μM INa IC50 μM Na/T IK IC50 μM K/T IC50 μM AFA-221 0.084 28.3 47% at 3.6 43 ~30 357 31% at 3 μM 1 μM AFA-281* 0.179 13.9 >30 31.35 >100 0.6 >100 >557 >100 >557 8 AFA-358 1.013 0.74 >30 >30 >30 >30 59% at 1 μM AFA-286* 0.069 20.1 2.52 4.63 27.83 9.7 8.7 127 >100 >1457 1.2 AFA-353 10.36 8.87 >100 >10 >100 >10 23% at 1 μM AFA-309* 0.141 4.2 15.61 >30 0% at 25.8 >30 >212 >30 >212 >30 3 μM AFA-279* 0.113 21.3 >10 83.45 76.4 0.19 >100 >1115 >100 >1115 6.7 AFA-258 0.195 17.6 >30 >30 21.43 >100 0.2 >100 >513 >100 >513 9.5 AFA-322* 0.138 25.6 3.09 51.64 23.5 0.15 14.3 103 >100 >723 9.2 AFA-206 0.067 8.2 20.3 303 6.8 102 50% at 1 μM h = human isoform; Use Dep = use dependent inhibition; DRG = dorsal root ganglion; hERG = human ether-a-go-go related gene (hERG) potassium (K+) channels -
-
- Avdonin P V, Buhler F R, Tkachuk V A (2000) Ca2+-agonistic effect of a T-type Ca-channel blocker mibefradil (Ro 40-5967). Membr Cell Biol 13:645-655.
- Caviedes B E, Herranz J L (2001) [Use of antiepileptic drugs in non epileptic disorders]. Rev Neurol 33:241-249.
- Chaplan S R, Bach F W, Pogrel J W, Chung J M, Yaksh T L (1994) Quantitative assessment of tactile allodynia in the rat paw. Journal of neuroscience methods 53:55-63.
- Chaudhry V, Rowinsky E K, Sartorius S E, Donehower R C, Cornblath D R (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Annals of neurology 35:304-311.
- Choi S, Na H S, Kim J, et al. (2007) Attenuated pain responses in mice lacking Ca(V)3.2 T-type channels. Genes Brain Behav 6:425-431.
- Cribbs L L, Gomora J C, Daud A N, Lee J H, Perez-Reyes E (2000) Molecular cloning and functional expression of Ca(v)3.1c, a T-type calcium channel from human brain. FEBS Lett 466:54-58.
- Decosterd I, Woolf C J (2000) Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87:149-158.
- Gomora J C, Daud A N, Weiergraber M, Perez-Reyes E (2001) Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol 60:1121-1132.
- Han H A, Cortez M A, Snead O C III. (2012) GABA B Receptor and Absence Epilepsy. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th edition. Bethesda (MD): National Center for Biotechnology Information (US)
- Huguenard J R (1998) Low-voltage-activated (T-type) calcium-channel genes identified. Trends Neurosci 21:451-452.
- Huguenard J R (2002) Block of T-Type Ca(2+) Channels Is an Important Action of Succinimide Antiabsence Drugs. Epilepsy Curr 2:49-52.
- Jagodic M M, Pathirathna S, Joksovic P M, Lee W, Nelson M T, Naik A K, Su P, Jevtovic-Todorovic V, Todorovic S M (2008) Upregulation of the T-type calcium current in small rat sensory neurons after chronic constrictive injury of the sciatic nerve. J Neurophysiol 99:3151-3156.
- Jagodic M M, Pathirathna S, Nelson M T, Mancuso S, Joksovic P M, Rosenberg E R, Bayliss D A, Jevtovic-Todorovic V, Todorovic SM (2007) Cell-specific alterations of T-type calcium current in painful diabetic neuropathy enhance excitability of sensory neurons. J Neurosci 27:3305-3316.
- Jarvis M F, Scott V E, McGaraughty S, Chu K L, Xu J, Niforatos W, Milicic I, Joshi S, Zhang Q, Xia Z (2014) A peripherally acting, selective T-type calcium channel blocker, ABT-639, effectively reduces nociceptive and neuropathic pain in rats. Biochemical pharmacology 89:536-544.
- Jenkins I D, Lacrampe F, Ripper J, Alcaraz L, Le P V, Nikolakopoulos G, de Almeida Leone P, White R H, Quinn R J (2009) Synthesis of four novel natural product inspired scaffolds for drug discovery. The Journal of organic chemistry 74:1304-1313.
- Kim S H, Chung J M (1992) An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain. 50(3):355-63.
- Kraus R L, Li Y, Gregan Y, Gotter A L, Uebele V N, Fox S V, Doran S M, Barrow J C, Yang Z Q, Reger T S, Koblan K S, Renger J J (2010) In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice. J Pharmacol Exp Ther 335:409-417.
- Latham J R, Pathirathna S, Jagodic M M, Choe W J, Levin M E, Nelson M T, Lee W Y, Krishnan K, Covey D F, Todorovic S M, Jevtovic-Todorovic V (2009) Selective T-type calcium channel blockade alleviates hyperalgesia in ob/ob mice. Diabetes 58:2656-2665.
- Lee M (2014) 2944: a first in class T-type calcium channel modulator for the treatment of pain. Journal of the peripheral nervous system: JPNS 19 Suppl 2:S11-12.
- Messinger R B, Naik A K, Jagodic M M, Nelson M T, Lee W Y, Choe W J, Orestes P, Latham J R, Todorovic S M, Jevtovic-Todorovic V (2009) In vivo silencing of the Ca(V)3.2 T-type calcium channels in sensory neurons alleviates hyperalgesia in rats with streptozocin-induced diabetic neuropathy. Pain 145:184-195.
- Nahab F B, Handforth A, Brown T, et al., (2012) Octanoic acid suppresses harmaline-induced tremor in mouse model of essential tremor. Neurotherapeutics, 9:635-638
- Nelson S C, Friedman H S, Oakes W J, Halperin E C, Tien R, Fuller G N, Hockenberger B, Scroggs M W, Moncino M, Kurtzberg J, et al. (1992) Successful therapy for trilateral retinoblastoma. Am J Ophthalmol 114:23-29.
- Perez-Reyes E (2003) Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev 83:117-161.
- Perez-Reyes E (2010) G protein-mediated inhibition of Cav3.2 T-type channels revisited. Molecular pharmacology 77:136-138.
- Perez-Reyes E, Van Deusen A L, Vitko I (2009) Molecular Pharmacology of Human Cav3.2 T-Type Ca2+ Channels: Block by Antihypertensives, Antiarrhythmics, and Their Analogs. Journal of Pharmacology and Experimental Therapeutics 328:621-627.
- Pexton T, Moeller-Bertram T, Schilling J M, Wallace M S (2011) Targeting voltage-gated calcium channels for the treatment of neuropathic pain: a review of drug development. Expert opinion on investigational drugs 20:1277-1284.
- Pogatzki-Zahn E M, Wagner C, Meinhardt-Renner A (2003) Spinal glutamate receptor antagonists differentiate primary and secondary mechanical hyperalgesia caused by incision. Pain 105(1-2):97-107.
- Sanguinetti, M C, Jiang C, Curran M E, Keating M T (1995) A mechanistic link between an inherited and an acquired cardiac arrhythmia: hERG encodes the IKr potassium channel. Cell, 81:299-307.
- Talley E M, Cribbs LL, Lee J H, Daud A, Perez-Reyes E, Bayliss D A (1999) Differential distribution of three members of a gene family encoding low voltage-activated (T-type) calcium channels. J Neurosci 19:1895-1911.
- Todorovic S M, Jevtovic-Todorovic V (2011) T-type voltage-gated calcium channels as targets for the development of novel pain therapies. British journal of pharmacology 163:484-495.
- Tringham E, Powell K L, Cain S M, Kuplast K, Mezeyova J, Weerapura M, Eduljee C, Jiang X, Smith P, Morrison JL, Jones N C, Braine E, Rind G, Fee-Maki M, Parker D, Pajouhesh H, Parmar M, O'Brien T J, Snutch T P (2012) T-type calcium channel blockers that attenuate thalamic burst firing and suppress absence seizures. Science translational medicine 4:121ra119.
- Uebele V N, Gotter A L, Nuss C E, Kraus R L, Doran S M, Garson S L, Reiss D R, Li Y, Barrow J C, Reger T S, Yang Z Q, Ballard J E, Tang C, Metzger J M, Wang S P, Koblan K S, Renger J J (2009) Antagonism of T-type calcium channels inhibits high-fat diet-induced weight gain in mice. J Clin Invest 119:1659-1667.
- Wang Y, Liu J J, Dransfield P J, Zhu L, Wang Z, Du X, Jiao X, Su Y, Li A R, Brown S P, Kasparian A, Vimolratana M, Yu M, Pattaropong V, Houze J B, Swaminath G, Tran T, Nguyen K, Guo Q, Zhang J, Zhuang R, Li F, Miao L, Bartberger M D, Correll TL, Chow D, Wong S, Luo J, Lin D C, Medina J C(2013) Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles. ACS medicinal chemistry letters 4:551-555.
- Xiang Z, Thompson A D, Brogan J T, Schulte M L, Melancon B J, Mi D, Lewis L M, Zou B, Yang L, Morrison R, Santomango T, Byers F, Brewer K, Aldrich J S, Yu H, Dawson ES, Li M, McManus O, Jones C K, Daniels J S, Hopkins C R, Xie X S, Conn P J, Weaver C D, Lindsley C W (2011) The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS chemical neuroscience 2:730-742.
- Xie X, Brogan J T, Schulte M L, Mi D, Yu H, Dawson E S, Li M, McManus O, Engers J, Lewis L M, Thompson A, Jones CK, Weaver C D, Lindsley C W (2010) Scaffold Hopping Affords a Highly Selective in vitro and in vivo T-Type Calcium Inhibitor Probe Free From IP Issues. In: Probe Reports from the NIH Molecular Libraries Program Bethesda (MD).
- Xie X, Lancaster B, Peakman T, Garthwaite J (1995) Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na+ channels and with native Na+ channels in rat hippocampal neurones. Pflugers Archiv: European journal of physiology 430:437-446.
- Xie X, Van Deusen A L, Vitko I, Babu D A, Davies L A, Huynh N, Cheng H, Yang N, Barrett P Q, Perez-Reyes E (2007) Validation of high throughput screening assays against three subtypes of Ca(v)3 T-type channels using molecular and pharmacologic approaches. Assay and drug development technologies 5:191-203.
- Yang Z Q, Barrow J C, Shipe W D, Schlegel K A, Shu Y, Yang F V, Lindsley C W, Rittle K E, Bock M G, Hartman G D, Uebele V N, Nuss C E, Fox S V, Kraus R L, Doran S M, Connolly T M, Tang C, Ballard J E, Kuo Y, Adarayan E D, Prueksaritanont T, Zrada M M, Marino M J, Graufelds V K, DiLella A G, Reynolds I J, Vargas H M, Bunting P B, Woltmann R F, Magee M M, Koblan K S, Renger J J (2008) Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels. J Med Chem 51:6471-6477.
- Yue J, Liu L, Liu Z, Shu B, Zhang Y (2013) Upregulation of T-type Ca2+ channels in primary sensory neurons in spinal nerve injury. Spine 38:463-470.
- Zhang Y F, Gibbs J W, 3rd, Coulter D A (1996) Anticonvulsant drug effects on spontaneous thalamocortical rhythms in vitro: ethosuximide, trimethadione, and dimethadione. Epilepsy Res 23:15-36.
Claims (11)
1. A method of treating hypersensitive cough, the method comprising the step of administering a therapeutically effective mount of a compound, or a pharmaceutically acceptable salt thereof, wherein the compound is:
4. The method of claim 1 , wherein the hypersensitive cough is caused by a disease or syndrome selected from the group consisting of COPD, asthma, GI reflux, post-nasal drip syndrome and chronic exposure to pollutants.
5. The method of claim 1 , wherein the compound is administered orally or nasally.
7. The method of claim 6 , wherein the itching is caused by atopic dermatitis, psoriasis, kidney failure, cholestasis, diabetes, leukemia, lymphoma, eczema, liver failure, anemia, thyroid disease, toxic plant exposure, chemical exposure, smog exposure, insect bites or allergic reaction to a food allergan.
8. The method of claim 6 , wherein the compound is administered orally or nasally.
10. The method of claim 9 , wherein the itching is caused by atopic dermatitis, psoriasis, kidney failure, cholestasis, diabetes, leukemia, lymphoma, eczema, liver failure, anemia, thyroid disease, toxic plant exposure, chemical exposure, smog exposure, insect bites or allergic reaction to a food allergan.
11. The method of claim 9 , wherein the compound is administered orally or nasally.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/460,648 US20230414586A1 (en) | 2018-08-28 | 2023-09-04 | Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/115,549 US11744825B2 (en) | 2018-08-28 | 2018-08-28 | Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds |
US18/460,648 US20230414586A1 (en) | 2018-08-28 | 2023-09-04 | Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/115,549 Division US11744825B2 (en) | 2018-08-28 | 2018-08-28 | Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230414586A1 true US20230414586A1 (en) | 2023-12-28 |
Family
ID=69639698
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/115,549 Active US11744825B2 (en) | 2018-08-28 | 2018-08-28 | Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds |
US18/460,648 Pending US20230414586A1 (en) | 2018-08-28 | 2023-09-04 | Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/115,549 Active US11744825B2 (en) | 2018-08-28 | 2018-08-28 | Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds |
Country Status (5)
Country | Link |
---|---|
US (2) | US11744825B2 (en) |
EP (1) | EP3843731A4 (en) |
JP (1) | JP7472143B2 (en) |
CN (1) | CN113365628A (en) |
WO (1) | WO2020047168A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2583715A1 (en) | 2011-10-19 | 2013-04-24 | Unomedical A/S | Infusion tube system and method for manufacture |
JP2023549134A (en) * | 2020-11-09 | 2023-11-22 | プラクシス プレシジョン メディシンズ, インコーポレイテッド | T-type calcium channel modulator and its use |
WO2023150703A2 (en) * | 2022-02-03 | 2023-08-10 | Praxis Precision Medicines, Inc. | Methods of treatment using t-type calcium channel modulators |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2018005242A (en) * | 2015-11-12 | 2019-03-18 | Afasci Inc | Ion channel inhibitory compounds, pharmaceutical formulations and uses. |
US20180235931A1 (en) | 2017-01-17 | 2018-08-23 | Menlo Therapeutics Inc. | Use of neurokinin-1 antagonists as antitussives |
-
2018
- 2018-08-28 US US16/115,549 patent/US11744825B2/en active Active
-
2019
- 2019-08-28 EP EP19854290.4A patent/EP3843731A4/en active Pending
- 2019-08-28 CN CN201980071612.0A patent/CN113365628A/en active Pending
- 2019-08-28 WO PCT/US2019/048666 patent/WO2020047168A1/en unknown
- 2019-08-28 JP JP2021535487A patent/JP7472143B2/en active Active
-
2023
- 2023-09-04 US US18/460,648 patent/US20230414586A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020047168A1 (en) | 2020-03-05 |
JP7472143B2 (en) | 2024-04-22 |
JP2022501417A (en) | 2022-01-06 |
EP3843731A4 (en) | 2022-05-11 |
CN113365628A (en) | 2021-09-07 |
US20200069665A1 (en) | 2020-03-05 |
EP3843731A1 (en) | 2021-07-07 |
US11744825B2 (en) | 2023-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230414586A1 (en) | Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds | |
KR102084109B1 (en) | A medicament for the treatment of influenza characterized by a combination of a cap-dependent endonuclease inhibitor and an anti-influenza drug | |
KR102630889B1 (en) | Solid Forms of Compounds That Modulate Kinases | |
KR102083857B1 (en) | New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | |
EP3386979B1 (en) | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of the task-1 and task-2 channels for treating sleep-related breathing disorders | |
US10562857B2 (en) | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | |
AU2018236275A1 (en) | Farnesoid X receptor agonists and uses thereof | |
Song et al. | Base promoted synthesis of novel indole-dithiocarbamate compounds as potential anti-inflammatory therapeutic agents for treatment of acute lung injury | |
CN105682655B (en) | Antimicrobial compounds | |
TW202229274A (en) | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
EP0910565A1 (en) | Amide derivatives as selective neuropeptide y receptor antagonists | |
KR20190031518A (en) | Substituted diazaheterobicyclic compounds and uses thereof | |
US11203597B2 (en) | Crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing | |
KR20160120790A (en) | Dihydropyridinone mgat2 inhibitors for use in the treatment of metabolic disorders | |
KR20100051678A (en) | Bicyclic amides for enhancing glutamatergic synaptic responses | |
BR112021000938A2 (en) | compound pharmaceutically acceptable salt, tautomer, isomer or stereoisomer thereof, pharmaceutical composition and process for the synthesis of said compound | |
US10829453B2 (en) | Antagonists of the kappa opioid receptor | |
AU2017280099A1 (en) | Activators of HIV latency | |
AU2022260554A1 (en) | Modulators of sortilin activity | |
CA3217317A1 (en) | Compounds | |
US9533973B2 (en) | Allosteric modulators of 5-hydroxytryptamine 2C receptor (5-HT2CR) | |
JP2019504016A (en) | Alkyldihydroquinolinesulfonamide compounds | |
TW202102502A (en) | Fused polycyclic pyridone compounds as influenza virus replication inhibitors | |
JP4817281B2 (en) | Parkinson's disease treatment | |
US10689381B2 (en) | Vinblastine 20″ amides: synthetic analogs that maintain or improve potency and simultaneously overcome Pgp-derived efflux and resistance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AFASCI, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:XIE, XINMIN;REEL/FRAME:064905/0319 Effective date: 20180830 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |